

Annual Report 2025/2026

There’s no insulin like your own

DIAMYD MEDICAL

Contents

1

Introduction **3**
Diamyd Medical – an overview 3
CEO comments 4
Type 1 diabetes 5
GAD65 manufacturing 7

2

Corporate governance **8**
The Diamyd Medical share 9
Board of Directors 11
Management and auditors 13

3

Financial **15**
Contents 16
Directors' Report 17
Multi-year overview 24
Definitions 24
Consolidated accounts 25
Parent Company accounts 29
Notes 33
Signatures 44
Auditor's Report 45

4

Other information **47**
Shareholder information 48




Introduction
→ Diamyd Medical – an overview
CEO comments
Type 1 diabetes
GAD65 manufacturing
Corporate governance +
Financial +
Other information +

Diamyd Medical – an overview

Diamyd Medical is a Swedish biotechnology company focused on precision medicine methods for type 1 diabetes and biomanufacturing. The Company's leading drug candidate in development is retogatein (GAD-alum), based on recombinant GAD65.

Diamyd Medical develops therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Retogatein (rhGAD65/alum) is an antigen-specific immunomodulatory therapy for the preservation of endogenous insulin production in individuals with the HLA DR3-DQ2 gene. Retogatein has demonstrated a favorable safety profile in more than 1,000 patients in clinical trials and works through antigen-specific immune tolerance without immunosuppression. Long-term results indicate the potential to delay the progression to symptomatic type 1 diabetes (Stage 3) and thus the need for insulin therapy by several years in children with the relevant genetic profile.

The Company operates from its headquarters in Stockholm, and its own manufacturing facility in Umeå. Diamyd Medical has established a 2,200 m² GMP-certified manufacturing facility in Umeå with authorization from the Swedish Medical Products Agency to manufacture biological investigational medicines. Large-scale technical batches of GAD65 have been produced and additional internal and external manufacturing projects are being evaluated to utilize the facility's capacity and expertise.




SWEDEN, UMEÅ

2,200 m²

MANUFACTURING FACILITY

SWEDEN, STOCKHOLM

HEADQUARTERS



NUMBER WITH TYPE 1 DIABETES

~60

MILLION PATIENTS

Of the 589 million[2] who today suffer from diabetes more than 10 percent have type 1 diabetes.

1) Includes individuals with adult-onset type 1 diabetes who are often misdiagnosed as type 2 diabetics.

2) IDF Diabetes Atlas 2025 – 11th edition

Introduction
Diamyd Medical – an overview
→ CEO comments
Type 1 diabetes
GAD65 manufacturing
Corporate governance +
Financial +
Other information +

CEO comments

Dear Shareholders,
The past year has been one of challenges, discipline, and renewed focus for Diamyd Medical. Following the decision to close the DIAGNODE-3 study, we acted decisively to reduce costs, preserve our financial strength, and reassess where we believe the Company can create the greatest shareholder value. Expenses associated with closing the study have now been taken, and based on our approved budget, our current cash position is expected to fund operations for more than two years.

I am pleased to share encouraging news regarding our retogatein (GAD-alum) drug candidate. A peer-reviewed publication in Diabetologia reported that retogatein may delay progression from early, non-insulin-requiring Type 1 Diabetes (Stage 1 and 2 T1D) to insulin-requiring Stage 3 disease by more than five years in a genetically defined subgroup. This randomized study evaluated individuals with GAD autoantibodies and at least one additional islet autoantibody who had not yet progressed to insulin-requiring disease. With this finding, Diamyd Medical is actively engaging with clinical investigators on the potential design of clinical trials seeking to identify individuals who match retogatein's genetically defined responder profile, persons who could represent a relevant population for future treatment. We are also continuing discussions with pharmaceutical companies that see potential strategic value in retogatein as a complement to their metabolic and autoimmune disease portfolios.

Given our strong cash position, we also evaluated a range of investment opportunities during the past quarter, both within and outside Type 1 Diabetes therapeutics, including other autoimmune disease areas. This process reaffirmed our belief that the Company's greatest strengths reside in its current drug candidates, including retogatein.

Retogatein has demonstrated a favorable safety profile across more than 15 clinical studies involving over 1,000 patients. Together with the encouraging results described above, these data strengthen our interest in developing retogatein as a potential therapy to delay or prevent progression to insulin-requiring Type 1 Diabetes. We believe this represents a logical path forward for Diamyd Medical to pursue. Another potential target population is patients with Latent Autoimmune Diabetes in Adults (LADA), which may account for approximately 10% of patients initially diagnosed with Type 2 Diabetes and may instead have autoimmune diabetes. We also remain open to participating with retogatein in investigator-initiated studies, and several discussions are ongoing. Taken together, the characteristics of retogatein provide a compelling basis for continued development: a long-term efficacy signal extending beyond five years; antigen-specific immune tolerance rather than broad immunosuppression; a favorable safety profile; an identified genetically defined responder group; and straightforward administration for patients.

Our GMP-approved biomanufacturing facility in Umeå is operational, with the next batch of retogatein drug substance scheduled for production before the end of the year. Diamyd Medical is open to working with partners on Contract Development and Manufacturing Organization projects, including those that contribute to preparedness and manufacturing capabilities in events such as pandemics.

The Company intends to remain open to selected, limited investments that have the potential to generate additional value over a two- to three-year horizon. Diamyd Medical currently holds investments in NextCell Pharma and Waterise.


Another recently formed initiative is the Company's development of DiaTrapper, an AI-based application trained using datasets from various Type 1 Diabetes-related research efforts. The application is one outcome of the Vinnova-financed ASSET project. It is intended to assess an individual's risk of progressing to Stage 3 Type 1 Diabetes over time.

Our priorities are clear: advance retogatein toward the market for the early stages of Type 1 Diabetes; expand our Biomanufacturing activities in Umeå to include additional projects; continue and broaden partner discussions; and remain open to limited investments in promising assets.

I look forward to the coming years with great enthusiasm. The long-term data strengthen our conviction that retogatein deserves continued development. At the same time, our financial position and focused strategy provide Diamyd Medical with a disciplined pathway to pursue that opportunity. I strongly believe in retogatein and its potential to make a meaningful difference for people at risk of progressing to insulin-requiring Type 1 Diabetes.

This optimism would not be possible without the support of two special groups deserving our appreciation. First, I thank our more than 18,000 shareholders and supporters, including Breakthrough T1D, for their continued support. I also want to express my sincere gratitude to the over 1,000 patients who have participated in clinical studies with retogatein as part of our efforts to combat autoimmune Type 1 Diabetes.

Stockholm,
November 12, 2026
Anders Essen-Möller, CEO




Introduction
Diamyd Medical – an overview
CEO comments
→ Type 1 diabetes
GAD65 manufacturing
Corporate governance +
Financial +
Other information +

Type 1 diabetes

Type 1 diabetes is an autoimmune disease that develops in three stages: silent autoimmunity, incipient dysglycemia and clinical diagnosis with lifelong insulin therapy. The investigational drug retogatein (GAD-alum) is being developed to address this entire spectrum by preserving endogenous insulin production.

Type 1 diabetes is an autoimmune disorder in which the immune system wrongly attacks endogenous insulin production. When the immune system attacks the body's own antigens in the insulin-producing beta cells of the pancreas, endogenous insulin production is gradually lost, raising blood glucose levels and eventually making insulin therapy necessary. While Type 1 diabetes most often presents during childhood or adolescence, at least as many adults are affected by the disease each year.

Type 1 diabetes: Asymptomatic autoimmunity, incipient deficiencies in blood glucose monitoring and clinical diagnosis requiring lifelong insulin therapy.



1) Sometimes referred to as stage 0.
2) Sometimes referred to as Stage 4.

Today, disease progression is usually divided into three stages:

Stage 1: The autoimmune process can be detected by **checking for the presence of** auto-antibodies to beta-cell antigens (such as testing for GAD65), but **blood glucose monitoring** remains normal and there are no symptoms. Some HLA types (such as HLA DR3-DQ2) are linked to a higher risk of reaching this stage.

Stage 2: Autoimmunity remains and **blood glucose monitoring** begins to fail. The condition is asymptomatic and can only be detected through active diagnostic testing.

Stage 3 (clinical type 1 diabetes): **Elevated blood glucose** and **symptoms**, diagnosis is made and insulin therapy is started.

Causes and diagnosis

The cause of type 1 diabetes is not entirely clear, but risk factors such as family history, genetics and certain viral infections have been identified. Type 1 diabetes is often diagnosed when only a limited amount of insulin production remains and insulin treatment must begin immediately. Auto-antibodies, against GAD65 for example, are used to identify presymptomatic stages and support diagnosis.

Introduction
Diamyd Medical – an overview
CEO comments
→ Type 1 diabetes
GAD65 manufacturing
Corporate governance +
Financial +
Other information +

Importance of preserved insulin production


Insulin is needed if cells are to absorb glucose from the blood and use it as energy. Preserved insulin production is essential for maintaining blood glucose levels and preventing complications. When production decreases or stops, glucose cannot be moved into the cells and glucose builds up in the blood.

With type 1 diabetes, detecting and preserving the insulin production that remains is important as this can help to stabilize blood glucose, reduce the risk of complications and make disease management easier.

When the body does not get enough insulin, it starts to break down fat to obtain energy. At the same time, ketones (acids that make the blood toxic) are formed. This can lead to ketoacidosis, a serious and potentially life-threatening condition characterized by dangerously high blood glucose and elevated ketone levels. Even a small amount of residual endogenous insulin production can dampen ketone formation and thereby reduce the risk of ketoacidosis.

The ability to produce even a small amount of your own insulin can also help prevent dangerously low blood glucose, known as hypoglycemia. If not treated quickly, this can be life-threatening.

Research shows that people with type 1 diabetes who still produce a certain amount of insulin are better protected against serious complications, such as long-term damage to the eyes, kidneys and heart.



Complications and treatment

People with type 1 diabetes have an increased risk of complications that can affect multiple organs and shorten life expectancy, especially in early onset. Severe complications include serious hypoglycemia and ketoacidosis. Long-term complications include cardiovascular disease, kidney failure, nerve damage and visual deterioration. Current treatments focus on keeping blood glucose balanced through own monitoring and externally administered insulin for type 1 diabetes. The treatment of type 1 diabetes is primarily based on insulin to regulate blood sugar levels. In the US, there is also an approved disease-modifying treatment that can delay the progression to symptomatic type 1 diabetes and slow the loss of endogenous insulin production in some patients.

Introduction
Diamyd Medical – an overview
CEO comments
Type 1 diabetes
→ GAD65 manufacturing
Corporate governance +
Financial +
Other information +

GAD65 manufacturing

Diamyd Medical's manufacturing facility in Umeå is part of the Company's ambition to be an integrated pharmaceutical company. The facility's primary purpose is to manufacture the recombinant GAD65, the active compound in retogatein.

As part of Diamyd Medical's ambition to be an integrated pharmaceutical company in selected markets, the Company has established a wholly owned manufacturing facility in Umeå via the Diamyd Biomanufacturing AB subsidiary. The property was acquired in 2021 and has undergone extensive refurbishment and repairs to meet the needs of the business. The primary purpose is the manufacture of recombinant GAD65, the active pharmaceutical ingredient (API) in retogatein. The 2,200 square-meter facility, which includes cleanrooms, laboratories, storerooms and office space facilitates full control, predictability and scalability of the manufacturing technology for retogatein (rhGAD65).

In-house production strengthens control across the supply chain

During the year, the Company continued to expand its manufacturing capabilities. Following an inspection by the Swedish Medical Products Agency, the Company received Good Manufacturing Practice (GMP) certification and manufacturing authorization for the production of investigational drugs for human use.

The certification and authorization confirm that the facility complies with relevant manufacturing requirements under current GMP regulations. This represents a crucial milestone in the Company's development and creates a platform for production with the quality and capacity required to meet regulatory requirements and future demand for retogatein.

Strategic establishment

The long-term goal is that the facility will become the commercial API manufacturing unit for retogatein, and also be a key player in the production of biological compounds for other drug projects. Employees at the facility are experts in areas such as cell cultivation and protein purification, which is paving the way for future implementations of precision medicine in type 1 diabetes. The facility has demonstrated the successful manufacturing of recombinant protein and has been inspected and approved by the Swedish Medical Products Agency. The manufacturing facility is ready to supply investigational materials for clinical trials and has an experienced team with expertise in process development, manufacturing, analytical development as well as quality control and quality assurance (QC/QA). Additional manufacturing of biological compounds for other drug projects, both internal and external, will be evaluated to make full use of the facility, platform, analytical and research laboratory and competencies.



Control and predictability of the manufacturing process

Diamyd Medical's Umeå facility uses the Baculovirus Expression Vector System (BEVS) in the complex manufacturing process of recombinant human GAD65 protein



Upstream process

Baculovirus-based expression system with insect cells



Downstream process

Clarification / Capture step
Polishing step / Nanofiltration



Quality Control

Pharmacopoeia and internal quality control methods

Introduction +
Corporate governance
The Diamyd Medical share
Board of Directors
Management and auditors
Financial +
Other information +



2 CORPORATE GOVERNANCE

Introduction +
Corporate governance
→ The Diamyd Medical share
Board of Directors
Management and auditors
Financial +
Other information +

The Diamyd Medical share

Diamyd Medical's shares are traded in the Health Care segment of Nasdaq First North Growth Market (ticker: DMYD B, ISIN code: SE0005162880).

Share and share capital


At August 31, 2026, the number of shares in Diamyd Medical was 154,984,500 (137,499,723), comprising 151,481,380 (133,996,603) Class B shares (one-tenth of a vote per share) and 3,503,120 (unchanged) Class A shares (one vote per share). The rounded quotient value of both Class A and Class B shares was SEK 0.1014 (unchanged). The shares are denominated in Swedish kronor (SEK). At the end of the financial year (August 31, 2026), the share capital amounted to KSEK 15,719 (13,945).

Share performance

The last price paid at August 31, 2026 was SEK 1.00 (11.30), generating a market cap of MSEK 151.5 (1,514) for Diamyd Medical calculated on the number of Class B shares. The highest price paid during the financial year was SEK 17.62 (19.34). The lowest price paid was SEK 1.00 (7.50). The average share price was SEK 7.55 (11.13).

During the financial year, 296,729,538 Class B shares (81,565,199) were traded on Nasdaq First North Growth Market.

Share performance Sep 1, 2025 – Aug 31, 2026



New share issues

Directed issues of Class B shares were carried out during the financial year to certain US sector-focused investors, through which the Company raised KSEK 233,347 before transaction costs. The LTI 2022 incentive scheme was completed during the financial year, and shares were allotted to participants at quotient value.

Following the share issues and the completion of LTI 2022, the number of shares in the Company increased to 154,984,500 (137,499,723) and share capital to KSEK 15,719 (13,945).

Ownership structure

At August 31, 2026, Diamyd Medical had 18,652 shareholders (19,428). The ten largest owners of Diamyd Medical held shares corresponding to 36.6% (32.5) of the capital and 38.9% (34.6) of the votes.

Dividend

The Board proposes that no dividend be paid for the 2025/2026 financial year.

Nasdaq First North Growth Market and certified adviser

First North Growth Market is an alternative marketplace for Nordic growth companies and is mainly designed for smaller and mid-sized companies. It does not have the same legal status as a regulated market and the regulatory framework is somewhat less extensive than the stock market's main marketplaces. All companies listed on Nasdaq First North Growth Market must have a Certified Adviser for guidance and support. Diamyd Medical's Certified Adviser is FNCA Sweden AB.

Introduction +
Corporate governance
→ The Diamyd Medical share
Board of Directors
Management and auditors
Financial +
Other information +

Data per share

	2025/26	2024/25
Share price, August 31, SEK	1.02	11.3
Share performance, %	–91	–31
Equity per share, SEK	1.6	2.0
Result per share, before and after dilution, SEK	–1.8	–1.5
Average no. of shares	145,174,897	112,524,911
No. of shares at August 31	154,984,500	137,499,723

Share capital trend at Aug 31, 2026

Year	Transaction	Share capital (increase, SEK)	Class A shares (increase)	Class B shares (increase)	Share capital (accumulated, SEK)
1984	The Company was founded	1,000,000		1,000,000	1,000,000
2013	Split		479,292	8,380,419	1,000,000
2013	New share issue	1,000,000	479,292	9,380,419	2,000,000
2015	New share issue[1)]	10,142		100,000	2,010,142
2015	New share issue	202,846		2,000,000	2,212,988
2015	New share issue[1)]	30,427		300,000	2,243,415
2016	New share issue	747,805	319,528	7,053,612	2,991,220
2017	New share issue	2,573,706	852,074	24,523,919	5,564,926
2017	New share issue[1)]	119,642		1,179,635	5,684,568
2017	New share issue[1)]	28,978		285,714	5,713,545
2018	New share issue[2)]	1,301,852	426,037	12,409,855	7,015,397
2021	New share issue	243,414		2,400,000	7,258,812
2021	New share issue	543,215		5,357,143	7,802,027
2023	New share issue	898,123		8,855,375	8,700,151
2023	New share issue	929,595	185,407	8,980,275	9,629,746
2024	New share issue	484,285	154,163	4,620,819	10,114,030
2024	New share issue[2)]	442,724	92,703	4,272,497	10,556,754
2025	New share issue[2)]	1,046		10,318	10,557,801
2025	New share issue	3,387,593	514,624	32,886,603	13,945,394
2026	New share issue[2)]	26,194	0	258,277	13,971,589
2026	New share issue	1,747,133		17,226,500	15,718,722
Total		**15,718,722**	**3,503,120**	**151,481,380**	

1) Offset issues. 2) Warrant redemption scheme.

Ownership structure by size of holding at August 31, 2026

Holding	Capital (%)	Votes (%)	No. of shares	No. of shareholders	Share (%)
1 – 100	0.12	0.10	188,038	4,890	26.22
101 – 200	0.17	0.14	257,568	1,716	9.20
201 – 300	0.19	0.16	294,414	1,149	6.16
301 – 400	0.19	0.16	294,820	831	4.46
401 – 500	0.22	0.19	348,154	751	4.03
501 – 1,000	1.16	0.97	1,802,870	2,369	12.70
1,001 – 2,000	1.97	1.64	3,055,687	2,073	11.11
2,001 – 5,000	4.63	3.84	7,168,882	2,183	11.70
5,001 – 10,000	5.25	4.36	8,131,442	1,104	5.92
10,001 – 20,000	6.91	5.74	10,697,639	739	3.96
20,001 –	79.19	82.71	122,744,986	847	4.54
Total	**100.00**	**100.00**	**154,984,500**	**18,652**	**100**


Ten largest shareholders at August 31, 2026

Name	Class A shares	Class B shares	Holding (%)	Votes (%)
Avanza Pension		18,090,969	11.67	9.70
Nordnet Pensionsförsäkring		10,985,401	7.09	5.89
Lindkvist, Bertil		10,200,000	6.58	5.47
Essen-Möller, Anders[1)]	1,235,620	5,797,192	4.54	9.73
Vestal Point Capital LP		2,111,386	1.36	1.13
Ra Capital Management LP		2,051,760	1.32	1.10
Point72 Asset Management		2,022,864	1.31	1.08
Mats Carlsson		1,545,026	1.00	0.83
Essen-Möller, Maria-Teresa	400,000	963,998	0.88	2.66
Nordnet Livforsikring AS		1,087,258	0.70	0.58
Total, ten largest owners	**1,635,620**	**54,855,854**	**36.45**	**38.18**
Other shareholders	1,867,500	96,625,526	63.55	61.82
Total	**3,503,120**	**151,481,380**	**100**	**100**

1) Anders Essen-Möller also owns 100,000 Class A shares via company.
Source: Monitor and Diamyd Medical AB

Introduction +
Corporate governance
The Diamyd Medical share
→ Board of Directors
Management and auditors
Financial +
Other information +

Board



Erik Nerpin

Chairman

Born in 1961
Bachelor of Laws, Master of Laws. Lawyer.

Self-employed with Advokatfirman Nerpin AB. Independent of the Company and its principal owner. Board member of Diamyd Medical since 2012.

Board assignments in listed companies:
Chair of Kancera AB, Hilbert Group AB, edyoutec AB and Neovici Holding AB and Board member of Effnetplattformen Holding AB.

Holding in Diamyd Medical at August 31, 2026:
97,804 Class B shares.

Anders Essen-Möller

Chief Executive Officer and Board member

Born in 1941
MSc. Founder of Diamyd Medical and CEO 1996–2007.

Independent of the Company, is a major owner. Also Chair of Diamyd Medical 2007–2015. Founder of Synectics Medical AB, which was divested to Medtronic, Inc. in 1996.

Holding in Diamyd Medical at August 31, 2026:
1,235,620 Class A shares (of which 100,000 via company), 5,797,192 Class B shares.

Maria-Teresa Essen-Möller

Board member

Born in 1970
MSc in Business Administration.

Independent of the Company, but not independent of its principal owner. Prior experience includes CEO of Health Solutions, Chief Commercial Officer at ScientificMed and Digital Marketing Manager at Sanofi. Board member of Diamyd Medical since 2009.

Holding in Diamyd Medical at August 31, 2026:
400,000 Class A shares, 963,998 Class B shares.

Torbjörn Bäckström

Board member

Born in 1948
Specialist physician in gynecology and obstetrics.

CEO of Zatisfield Health AB. Independent of the Company and its principal owner. Board member since 2017. Head of Neurosteroid Research Centre in Umeå and professor emeritus at the Department of Clinical Science, Obstetrics and Gynecology at Umeå University.

Holding in Diamyd Medical at August 31, 2026:
2,342 Class B shares and 468 TO5B via company.

Introduction +
Corporate governance
The Diamyd Medical share
→ Board of Directors
Management and auditors
Financial +
Other information +



Mark Atkinson

Board member

Born in 1961
PhD. Professor of Diabetes Research, Department of Pathology, Immunology and Laboratory Medicine, University of Florida, USA.

American Diabetes Association Eminent Scholar for Diabetes Research.

Independent of the Company and its principal owner. Board member since 2018.

Holding in Diamyd Medical at August 31, 2026:
16,750 Class B shares.

Karin Hehenberger

Board member

Born in 1972
M.D., PhD, Karolinska Institutet.

Post-doc at Joslin Diabetes Center, Harvard Medical School. Chief Medical Officer, Patient Care America, President and founder of Lyfebulb, Board member of 3B Future Health Ventures Scientific Advisory Board, Board member of Anacardio AB, advisor to Astorg Philanthropic foundation.

Independent of the Company and its principal owner. Board member since 2021.

Holding in Diamyd Medical at August 31, 2026:
10,000 Class B shares.

Karin Rosén

Board member

Born in 1967
MD, PhD, Lund University.

More than 20 years of experience in senior positions in Global Clinical Development and US & Global Medical Affairs with Horizon Therapeutics, GlaxoSmithKline, Aimmune Therapeutics and Genentech (a member of the Roche Group).

Independent of the Company and the principal owners. Board member since 2023.

Holding in Diamyd Medical at August 31, 2026:
18,370 Class B shares.

Introduction +
Corporate governance
The Diamyd Medical share
Board of Directors
→ Management and auditors
Financial +
Other information +

Management and auditors



Anders Essen-Möller

Chief Executive Officer and Board member

Born in 1941
MSc. Founder of Diamyd Medical and CEO 1996–2007.

Independent of the Company, is a major owner. Also Chair of Diamyd Medical 2007–2015. Founder of Synectics Medical AB, which was divested to Medtronic, Inc. in 1996.

Holding in Diamyd Medical at August 31, 2026: 1,235,620 Class A shares (of which 100,000 via company), 5,797,192 Class B shares.

Mathias Skalmstad

Chief Financial Officer

Born in 1973.
MSc in Business Administration from Mälardalens University.

Prior experience includes more than 25 years of work at companies in the life sciences, technology, education, automotive and telecom sectors, in Sweden and internationally.

Joined Diamyd Medical in 2026.

Holding in Diamyd Medical at August 31, 2026:
-

Martina Widman

Chief Operating Officer

Born in 1981
MSc in Mechanical Engineering from the Royal Institute of Technology in Stockholm, with a specialization in biomedical engineering.

Prior experience of clinical activities in the pharmaceutical industry. Joined Diamyd Medical in 2008.

Holding in Diamyd Medical at August 31, 2026:
27,487 Class B shares.

Anton Lindqvist

Chief Scientific Officer


Born in 1980
MSc in Molecular Biotechnology from Uppsala University.

Research experience from University of Pittsburgh, Uppsala University, the Royal Institute of Technology and Karolinska Institutet. Prior experience in managing technical development at several biotech companies.

Joined Diamyd Medical in 2013.

Holding in Diamyd Medical at August 31, 2026:
10,300 Class B shares.

Introduction +
Corporate governance
The Diamyd Medical share
Board of Directors
→ Management and auditors
Financial +
Other information +



Sofia Mayans

Head of Manufacturing Site

Born in 1976.
PhD in Human Genetics
from Umeå University.

Prior experience from senior positions and business development in the life science sector. Academic research experience in the fields of genetics and immunology from Umeå University, Copenhagen University and La Jolla institute for Immunology.

Joined Diamyd Medical in 2024.

Holding in Diamyd Medical at August 31, 2026:
3,369 Class B shares.

Martin Linhult

CMC Lead/Manufacturing Manager

Born in 1972
PhD in Molecular Biotechnology from KTH Royal Institute of Technology in Stockholm.

Prior experience includes more than 20 years of work in the pharmaceutical and biotech sectors.

Joined Diamyd Medical in 2023.

Holding in Diamyd Medical at August 31, 2026:
12,440 Class B shares.

Magnus Forssén

Facility Manager

Born in 1971
Licentiate Degree in Molecular Biology from Umeå University.

More than 20 years of prior experience in the pharmaceutical industry and the life sciences sector.

Joined Diamyd Medical in 2022.

Holding in Diamyd Medical at August 31, 2026:
10,440 Class B shares.

Auditors

The Company's auditors are BDO Mälardalen AB, Box 24193, SE-104 51 Stockholm, Sweden. Johan Pharmanson (born in 1964) is Auditor in Charge.

Introduction +
Corporate governance +
Financial
Contents
Directors' Report
Multi-year overview
Definitions
Consolidated accounts
Parent Company accounts
Notes
Signatures
Auditor's Report
Other information +



3

FINANCIAL

Introduction +

Corporate governance +

Financial

→ Contents

Directors' Report

Multi-year overview

Definitions

Consolidated accounts

Parent Company accounts

Notes

Signatures

Auditor's Report

Other information +

Contents

Directors' Report		17
Multi-year overview		24
Definitions		24
Consolidated income statement		25
Consolidated balance sheet		26
Consolidated cash flow statement		27
Consolidated change in equity		28
Parent Company income statement		29
Parent Company balance sheet		30
Parent Company cash flow statement		31
Parent Company change in equity		32
Notes		33
Note 1	Recognition and measurement principles	33
Note 2	Estimates and judgments	35
Note 3	Operating income	35
Note 4	Personnel costs	36
Note 5	Related-party transactions	37
Note 6	Auditor's fees	37
Note 7	Leases	37
Note 8	Patents	38
Note 9	Financial income	38
Note 10	Income tax	38
Note 11	Land and buildings	39
Note 12	Construction in progress	39
Note 13	Machinery and equipment	39
Note 14	Participations in subsidiaries	40
Note 15	Participations in associates	40
Note 16	Other long-term securities	41
Note 17	Long-term receivables from subsidiaries	41
Note 18	Other long-term receivables	41
Note 19	Prepaid expenses and accrued income	42
Note 20	Share capital	42
Note 21	Provisions	42
Note 22	Total long-term liabilities	42
Note 23	Accrued expenses and deferred income	43
Note 24	Pledged assets and contingent liabilities	43
Note 25	Significant events after the end of the financial year	43
Note 26	Appropriation of profit/loss	43
Signatures of the Board of Directors and Chief Executive Officer		44

Introduction +
Corporate governance +
Financial
Contents
→ Directors' Report
Multi-year overview
Definitions
Consolidated accounts
Parent Company accounts
Notes
Signatures
Auditor's Report
Other information +

Directors' Report

The Board of Directors and Chief Executive Officer of Diamyd Medical AB, with its registered office in Stockholm, Sweden, Corporate Registration Number 556242-3797, hereby present their financial statements for the financial year of September 1, 2025–August 31, 2026.

INTRODUCTORY INFORMATION

This annual report encompasses the Group (the "Group", "Company" or "Diamyd Medical"), which includes Diamyd Medical AB, Corp. Reg. No. 556242–3797, and the subsidiary Diamyd Biomanufacturing AB, Corp. Reg. No. 559041-0931. Personnel are employed by the Parent Company. Services billed in the Group are based on resource utilization. Diamyd Medical's Class B shares are traded on Nasdaq First North Growth Market under the DMYD ticker. The Company's Certified Adviser is FNCA Sweden AB.

ACTIVITIES

Diamyd Medical develops precision medicine therapies to prevent and treat type 1 diabetes. The Company's portfolio includes retogatein (rhGAD65) and Remygen (GABA).

Diamyd Medical's development in the field of diabetes is based on GAD (glutamic acid decarboxylase, 65kDa isoform), a human enzyme that plays an important role in the disease process in autoimmune forms of diabetes, type 1 diabetes and LADA. Retogatein (rhGAD65) is an antigen-specific immunotherapy with precision medicine focus for type 1 diabetes in individuals who carry the HLA DR3-DQ2 genotype. Retogatein has Orphan Drug Designation in the US and Fast Track Designation from the US Food and Drug Administration (FDA) for the treatment of type 1 diabetes in Stages 1, 2 and 3. Stages 1 and 2 are early, presymptomatic stages of the disease, before daily insulin therapy is required, while Stage 3 is symptomatic type 1 diabetes that requires insulin therapy.

Remygen (GABA) is an oral investigational drug with potential regenerative and immunomodulation efficacy for treatment of both type 1 and type 2 diabetes. Remygen has been evaluated in a Phase 1/2 clinical trial in individuals with type 1 diabetes in Stage 3 who have been insulin-dependent for several years. The study demonstrated a favorable safety profile and also collected data on restoring or stimulating endogenous insulin production and preventing hypoglycemia.

Clinical development

During the 2025/2026 financial year, retogatein was evaluated in the Phase 3 DIAGNODE-3 trial in individuals with new-onset type 1 diabetes in Stage 3 who carry the HLA DR3-DQ2 haplotype. The pre-specified interim analysis included 174 out of 321 participants enrolled in the study. The primary efficacy analysis did not achieve statistical significance, and the criteria for continuing the study were not met. Based on the results, the Company therefore decided to discontinue DIAGNODE-3 early due to futility, in accordance with the study's decision-making framework. No new safety concerns were identified. Previous Phase 2 and Phase 3 trials have generated clinical data supporting an effect on the preservation of endogenous insulin production in this genetically defined subpopulation.

Long-term follow-up of the DiAPREV-IT study (2009–2016), which included 50 children with type 1 diabetes in Stage 1 or 2, has shown that retogatein delayed progression to Stage 3, insulin-dependent type 1 diabetes, by more than five years in a genetically defined subgroup carrying the HLA DR3-DQ2 genotype. After a median follow-up of almost 13 years, children in this subgroup who received two injections of retogatein under the skin developed type 1 diabetes in Stage 3 after an estimated 9.0 years, compared with 3.4 years for those who received placebo.

ASSET (AI for Sustainable Prevention of Autoimmunity in the Society)

The five-year ASSET project, which was coordinated by Diamyd Medical and funded by VINNOVA, was concluded in September 2026. The project studied how AI, screening and data-driven risk assessment can enable earlier detection and prevention of type 1 diabetes. Within the context of ASSET, the DiaPrecise Phase II trial evaluated the safety and feasibility of treatment with retogatein in the presymptomatic type 1 diabetes in Stage 1 or 2 in individuals who carry the HLA DR3-DQ2 genotype. The project has helped to link screening and the identification of individuals in the early stages of disease, providing opportunities for preventive precision medicine treatment.

In-house manufacturing of GAD65

Diamyd Medical has established a 2,200 m² biomanufacturing facility in Umeå to manufacture recombinant GAD65. The facility has received GMP certification and a manufacturing license from the Swedish Medical Products Agency to manufacture biological investigational medicines for human use. Large-scale technical batches of GAD65 have been produced, and the facility provides capacity to develop and manufacture biological medicines. Additional biomanufacturing projects, both internal and external, will be evaluated to make full use of the site, platform, analytical laboratory and competencies.

Introduction +
Corporate governance +
Financial
Contents
→ Directors' Report
Multi-year overview
Definitions
Consolidated accounts
Parent Company accounts
Notes
Signatures
Auditor's Report
Other information +

Shares and participations in other companies
Diamyd Medical owns shares in NextCell Pharma AB (Corporate Registration Number 556965–8361), which develops stem cell therapies and runs a stem cell bank for privately banked stem cells. At August 31, 2026, the carrying amount of the holding in the Parent Company amounted to MSEK 4.7. The share of capital and voting rights on the same date was approximately 4%.

Diamyd Medical owns shares in Waterise B.V. (trade register number 88419398), which specializes in providing sustainable solutions for fresh water through innovative desalination technology. At August 31, the carrying amount of the holding in the Parent Company amounted to approximately MSEK 4.4.

During the year, an impairment was recognized of the holding in MainlyAI AB (Corp. Reg. No. 559258-7538), reducing the value from MSEK 1.3 to 0 due to bankruptcy.

EVENTS DURING THE FINANCIAL YEAR

- In September, the second annual conference on screening for type 1 diabetes (the ASSET project) was held, coordinated by Diamyd Medical
- In September, Eurasia granted Diamyd Medical a precision medicine patent for an insulin antigen treatment in type 1 diabetes
- In September, an analysis was presented at the European Association for the Study of Diabetes (EASD) that supports Diamyd's potential to delay the progression of Stage 3 type 1 diabetes
- In October, Hong Kong granted Diamyd Medical a precision medicine patent for an insulin antigen treatment in type 1 diabetes
- In November, Diamyd Medical marked World Diabetes Day with expert panel on the future of type 1 diabetes treatment
- In November, Diamyd Medical reported that its pivotal Phase 3 type 1 diabetes trial had cleared the last safety review ahead of early readout in March 2026.
- In December, Diamyd Medical AB held its Annual General Meeting
- In December, Diamyd Medical reported that it had completed Phase 3 screening and that the GMP review was proceeding
- In December, Diamyd Medical reported that it is accelerating the primary efficacy readout by nine months in its type 1 diabetes Phase 3 trial following alignment and guidance from the FDA
- In January, Diamyd Medical reported that its lead immunotherapy for type 1 diabetes would receive the global non-proprietary name retogatein
- In January, Diamyd Medical reported that it had completed screening in the pivotal Phase 3 DIAGNODE-3 trial
- In January, Diamyd Medical reported that it is deepening its long-term manufacturing collaboration for retogatein
- In February, a Notice of Allowance was received for a key retogatein US patent
- In February, the finalization of the database for the interim analysis in the Phase 3 DIAGNODE-3 trial was announced
- In March, the American Diabetes Association's 86th Scientific Sessions featured Diamyd Medical's retogatein Phase 3 trial in a dedicated symposium
- In March, Diamyd Medical received a Notice of Grant in Japan for an insulin-based antigen therapy patent in type 1 diabetes
- In March, Diamyd Medical entered into equity financing agreements with new US sector-focused investors for up to MUSD 125 and announced full enrollment in its Phase 3 trial
- In March, negative interim results were reported from the Phase 3 DIAGNODE-3 trial
- In March, an update was provided on the interim efficacy analysis of the Phase 3 DIAGNODE-3 trial
- In April, the 2026 Extraordinary General Meeting was held
- In April, it was announced that the DIAGNODE-3 trial was being discontinued following an evaluation that confirmed futility A strategic review was initiated
- In April, changes were announced to the Company's governance and leadership
- In May, Diamyd Medical reported that it is strengthening its position in the manufacturing of biological medicines – positive feedback from the Swedish Medical Products Agency
- In May, an update was provided on the strategic review and financial position

Introduction +
Corporate governance +
Financial
Contents
→ Directors' Report
Multi-year overview
Definitions
Consolidated accounts
Parent Company accounts
Notes
Signatures
Auditor's Report
Other information +

- In May, Diamyd Medical received GMP certification and manufacturing authorization for biological investigational medicinal products for human use
- In May, it was announced that Niklas Axelsson had decided to leave his position as CFO
- In June, an update was provided on ongoing activities
- In June, a Notice of Allowance was received for the key precision medicine patent
- In June, an update was provided on the strategic review
- In June, it was announced that Mathias Skalmstad will take up the position of new CFO
- In July, an update was provided on the learnings from the DIAGNODE-3 interim analysis

EVENTS AFTER THE END OF THE FINANCIAL YEAR

- In September 2026, it was announced that results from the DiAPREV-IT study show that Diamyd's retogatein delays the onset of insulin-dependent type 1 diabetes for more than five years

FINANCIAL INFORMATION, GROUP

Revenues
Revenues amounted to MSEK 4.7 (5.0). See also Note 3.

Research and development costs
Research and development (R&D) costs is the largest cost item in Diamyd Medical and amounted to MSEK –180.1 (–119.5), or about 69% (64) of total operating expenses. The higher costs year-on-year largely reflect that all 57 clinics in Europe and the US in the Phase 3 DIAGNODE-3 trial were active.

Results
The Company posted a loss of MSEK –255.6 (–169.8) for the year.

Financial position
At August 31, 2026, cash and cash equivalents and short-term investments amounted to MSEK 305.4 (277.2). Equity amounted to MSEK 243.6 (280.0).

Result from shares and participations
At August 31, 2026, Diamyd Medical had an ownership interest of approximately 4.0% (5.0) in NextCell Pharma AB. The carrying amount of the holding amounted to MSEK 4.7 (6.0).

During the year, an impairment was recognized of the holding in MainlyAI AB, reducing the value from MSEK 1.3 to 0 due to bankruptcy.

Diamyd Medical did not receive any dividends from its holdings during the financial year.

ORGANIZATION

At August 31, 2026, the Company had 36 (39) full-time equivalents. The average number of employees during the year was 42 (33). Personnel costs amounted to MSEK –52.4 (–39.2). For more information about salaries, other compensation and social security contributions, refer to Note 4.

PERFORMANCE-BASED SHARE PROGRAM,

LTI 2022
The LTI 2022 incentive scheme was completed during the financial year, and shares were allotted to participants at quotient value.

LTI 2024
At August 31, 2026, the Company had granted 45 participants performance share rights in accordance with LTI 2024. A total of 450,000 performance share rights have been granted. The LTI 2024 rights were valued on the allotment date at the fair value of the allotted equity instrument. At August 31, 2026, social security contributions for LTI 2024 amounted to MSEK 0.0 and personnel costs to approximately MSEK 1.71 for the period. The personnel costs were based on the allotment value, simulated using the Monte Carlo method.

Board LTI 2024
At August 31, 2026, the Company had granted 6 participants performance share rights in accordance with Board LTI 2024. A total of 60,000 performance share rights have been granted. Board LTI 2024 rights were valued on the allotment date at the fair value of the allotted equity instrument. At August 31, 2026, social security contributions for Board LTI 2024 amounted to MSEK 0.0 and personnel costs to approximately MSEK 0.21 for the period. The personnel costs were based on the allotment value, simulated using the Monte Carlo method.

RISK FACTORS

Drug development is usually a lengthy and capital-intensive process entrenched with a high degree of

Introduction +
Corporate governance +
Financial
Contents
→ Directors' Report
Multi-year overview
Definitions
Consolidated accounts
Parent Company accounts
Notes
Signatures
Auditor's Report
Other information +

uncertainty due to the high degree of unpredictable and complex parameters of biological and medical processes. The following risks include both internal and external factors, with no order of precedence, that could have a material adverse impact on Diamyd Medical's operations, financial position and results.

Commercial risk and development risk
It cannot be guaranteed that the research and development projects and clinical trials the Company is involved in will result in products that can be approved and launched on the market, or that these products, once launched, will be commercially successful in any or all markets due to the inability to agree on pricing, a changed competitive situation or that the Company alone or in collaboration with any partner does not succeed in marketing its products.

Clinical trials
The Company has concluded, and intends to conclude, agreements with various providers of clinical trial services conducted at clinics and hospitals. There is a risk that current and future suppliers will not deliver as contracted, which could lead to delays and increased costs. Should agreements with partners be terminated, there is no guarantee that these agreements can be replaced with other suppliers within a reasonable period of time, which could delay the clinical trials and, in turn lead to increased costs for the Company and delays in possible future revenues. A key component of clinical trials is the recruitment of trial participants.

Financial risk
Diamyd Medical has no products on the market and the Company has not yet generated any profits. At August 31, 2026, the Group had cash and cash equivalents and short-term investments of MSEK 305.4 (277.2). Despite the stronger financial position, the Company's increasing level of activity, in particular resulting from the positive response from the FDA regarding the opportunity to apply for earlier marketing authorization, has increased costs. However, these cost increases may reduce the risk of delays in commercialization and manufacturing. Diamyd Medical may seek additional financing from investors by issuing new shares, which may result in dilution for existing shareholders.

Liquidity risk
Liquidity risk is the risk that the Diamyd Medical will be unable to meet its short-term payment commitments. Liquidity risk is limited through liquidity planning and investments in financial instruments that can be redeemed at short notice. Investments may only be made in interest-bearing securities with low credit risk. In addition, there are limitations for how much may be invested in a single counterparty to avoid a concentration of credit risk. In accordance with the Company's financial policy, surplus liquidity is invested in bank deposits and in commercial papers with a rating of at least A- (S&P) and maturities of up to one year.

Currency risk
Diamyd Medical's accounting and functional currency is SEK. A relatively large share of the Company's development costs are paid in EUR and USD. As a result, the Company is exposed to foreign exchange risk in relation to cash flow within and outside Sweden and the euro-zone, such as fluctuations in the exchange rate between the date on which an agreement was signed and the date on which payment is made under an agreement. In accordance with the Company's policy for financial risk, the Company exchanges 25–50% of the projected flows in USD and EUR.

Share-related risks
An investment in Diamyd Medical is associated with risk and the share price may rise as well as fall. As a result, an investor may lose all or some of their invested capital. Between September 1, 2025 and August 31, 2026, the lowest price paid for the Company's share was SEK 1.00 and the highest price paid was SEK 17.62. The share price may fluctuate due to the results of clinical trials, the general economic situation and changes in the stock market's interest in the Company and its share. The share price may therefore be affected by factors that are wholly or partially beyond the Company's control. An investment in shares in Diamyd Medical should therefore be preceded by a careful analysis of the Company, its competitors and business environment, general information about the industry, the general economic situation and other relevant information. There is a risk that shares in Diamyd Medical cannot be sold at a price that is acceptable to the shareholder.

Production risk
The production of an investigational drug for clinical trials requires production of the actual compound in adequate quantities and adequate quality. There is also

Introduction +
Corporate governance +
Financial
Contents
→ Directors' Report
Multi-year overview
Definitions
Consolidated accounts
Parent Company accounts
Notes
Signatures
Auditor's Report
Other information +

a risk that Diamyd Medical will be unable to meet this need at a reasonable cost at any given time, which will affect the Company's ability to demonstrate the safety and efficacy of its investigational drugs in clinical trials, which could also delay clinical programs and commercialization and have a material adverse effect on the Company's operations, financial position and results. In 2020, Diamyd Medical started up a facility in Umeå to manufacture recombinant rhGAD65, the active ingredient in Diamyd®. The operation is under development and there is no guarantee it will be completed in time, or achieve the certification and authorization required for the manufacture of materials for market needs.

Intellectual property (IP) risk
There is no guarantee that the Company will develop products that can be patented or that the license rights to a patent can be maintained, renewed or provide sufficient protection for current or future discoveries. There is no guarantee that disputes over agreements or patents can be avoided or that any disputes arising can be settled in favor of the Company.

Key-person risk
Diamyd Medical is heavily reliant on key individuals. There is a risk that the Company's projects will be delayed or prematurely terminated if these individuals leave the Company or are unable to fulfill their duties for any other reason. New recruitment may also take considerable time to implement. There is also a risk that the Board, management or other key individuals may make bad decisions that could have an adverse effect on the Company.

Partnership, licensing and acquisition risk
Diamyd Medical's drug development strategy is based on licensing projects that have reached a certain stage of development to partners. The Company may also in-license or acquire projects, products or companies. There is no guarantee that Diamyd Medical will succeed in concluding partnerships and/or license agreements, and/or make acquisitions on commercial terms that are favorable for Diamyd Medical.

Regulatory approval risk
There is no guarantee that regulatory requirements with regard to the level of detail, amount of documentation or otherwise will remain unchanged. Such regulatory requirements may apply to the industry in general, or to Diamyd Medical specifically, and could result in higher costs and the delay or termination of projects.

Legal risk
Diamyd Medical's success is partly dependent on whether the Company's rights, such as patents and other contractual rights, can be safeguarded. This means that the Company may sometimes be forced to pursue litigation. There is no guarantee that such disputes can be settled in favor of the Company.

CORPORATE GOVERNANCE

Diamyd Medical is a Swedish public company.

Corporate governance is based on Swedish law, internal rules and instructions, Nasdaq First North Growth Market's Issuer Rules and other applicable rules. Since the Company's shares have been admitted to trading on Nasdaq First North Growth Market, Diamyd Medical is under no obligation to apply the Swedish Corporate Governance Code. Corporate governance is the framework of rules, practices and procedures by which Diamyd Medical is directed and controlled, attains the Company's objectives and creates value. The purpose of corporate governance is to assure shareholders and other stakeholders that the decisions made by the Company are characterized by trust, effective management and control, transparency, clarity and good business ethics.

Annual General Meeting
Under the Swedish Companies Act, the Annual General Meeting is the Company's highest decision-making body. At the Annual General Meeting, the shareholders exercise their right to vote on matters submitted to the Meeting, such as the adoption of income statements and balance sheets, appropriation of the Company's profit, discharge from liability for members of the Board and the Chief Executive Officer, the election of Board members and auditors, and remuneration of the Board and auditors. In addition to the Annual General Meeting, Extraordinary General Meetings may also be held.

Board of Directors
Under the Swedish Companies Act, the Board of Directors is responsible for the Company's organization and for directing the Company's affairs. The Board is responsible for continuously assessing the Company's operations and financial situation. The key role of the Board is to act on behalf of the Company's shareholders to ensure that the owners' expectations of long-term, satisfactory returns are met. Diamyd Medical's Board should consist of between three and eight members.

Introduction +
Corporate governance +
Financial
Contents
→ Directors' Report
Multi-year overview
Definitions
Consolidated accounts
Parent Company accounts
Notes
Signatures
Auditor's Report
Other information +

The Board held 23 (16) minuted meetings during the 2025/2026 financial year. The matters addressed included financing, production and other investment-related issues, regulatory issues and the Phase 3 program, annual and interim reports, information and communication. In addition to the minuted meetings, the Chairman of the Board and other Board members maintained regular contact with the Company's CEO. The Board received regular reports on the Company's financial position, in accordance with specific reporting instructions.

Chief Executive Officer
The Chief Executive Officer (CEO) is responsible for overseeing the day-to-day administrative and operational functions of the business, and leading the Company in accordance with the Board's guidelines and decisions. In addition to the delegation of responsibilities that is generally applicable under the Swedish Companies Act, the CEO's instructions regulate the duty and obligation to provide the Board with information and the necessary support for decision-making, the role of Secretary at Board meetings, the duty and obligation to ensure compliance with the Board's decisions regarding objectives, mission, strategic plans, and other guidelines, and the proposal of reviews thereof to the Board.

Internal control
The Board is responsible for the Company's internal control. The internal control system includes control of Diamyd Medical's organization, procedures and activities. The purpose is to ensure reliable and accurate financial reporting, that the Company's financial statements are prepared in accordance with the law and applicable accounting standards, and that other requirements are followed. The internal control system also aims to monitor compliance with Diamyd Medical's policies and instructions. In addition, the protection of the Company's assets is monitored, and it is ensured that the Company's resources are used in a cost-efficient and otherwise appropriate manner.

Risk management
Risk management is part of the Board and the CEO's internal governance and control of the operations. It involves identification of the most important risks associated with implementation of the Company's strategy and overall objectives, as well as other risks. Refer to the section on "Risk factors" above. Strategic risks are managed directly by the CEO as part of the day-to-day operations. The Board monitors exposure to these risks to ensure an ability to achieve strategies and objectives. The CEO is responsible for the ongoing management of all operational risks, and for ensuring that action plans are implemented when necessary to eliminate or minimize the impact of the risks identified.

THE SHARE

Share and share capital
At August 31, 2026, the number of shares in Diamyd Medical was 154,984,500 (137,499,723), comprising 151,481,380 (133,996,603) Class B shares (one-tenth of a vote per share) and 3,503,120 (unchanged) Class A shares (one vote per share). The rounded quotient value of both Class A and Class B shares was SEK 0.1014 (unchanged). The shares are denominated in Swedish kronor (SEK). At the end of the financial year (August 31, 2026), the share capital amounted to KSEK 15,719 (13,945).

Share performance
The last price paid at August 31, 2026 was SEK 1.00 (11.30), generating a market cap of MSEK 151.5 (1,514) for Diamyd Medical calculated on the number of Class B shares. The highest price paid during the financial year was SEK 17.62 (19.34). The lowest price paid was SEK 1.00 (7.50). The average share price was SEK 7.55 (11.13).

During the financial year, 296,729,538 Class B shares (81,565,199) were traded on Nasdaq First North Growth Market.

New issue
Directed issues of Class B shares were carried out during the financial year to certain US sector-focused investors, through which the Company raised KSEK 233,347 before transaction costs. The LTI 2022 incentive scheme was completed during the financial year, and shares were allotted to participants at quotient value.

Following the share issues and the completion of LTI 2022, the number of shares in the Company increased to 154,984,500 (137,499,723) and share capital to KSEK 15,719 (13,945).

Ownership structure
At August 31, 2026, Diamyd Medical had 18,652 shareholders (19,428). The ten largest owners of Diamyd Medical held shares corresponding to 36.6% (32.5) of the capital and 38.9% (34.6) of the votes. Both Class A and Class B shares are freely transferable.

Introduction +
Corporate governance +
Financial
Contents
→ Directors' Report
Multi-year overview
Definitions
Consolidated accounts
Parent Company accounts
Notes
Signatures
Auditor's Report
Other information +

THE COMPANY'S FUTURE DEVELOPMENT

At the end of the financial year, Diamyd Medical's cash and cash equivalents and short-term investments amounted to MSEK 305.4 (277.2). Based on the current financial position and the Group's strategy for the coming years, the Board of Directors sees no need for additional financing over the next 12 months.

PROPOSED ALLOCATION OF NON-RESTRICTED EQUITY

According to the balance sheet, the Parent Company's non-restricted equity amounts to the following:

SEK	
Share premium reserve	1,099,379,151
Retained earnings	–613,885,931
Result for the year	–255,147,828
Non-restricted equity	**230,345,392**

The Board proposes that the Company's retained earnings of SEK 230,345,392 be carried forward. The Company's earnings for the financial year and financial position at August 31, 2026 are presented in the following income statement and balance sheet, cash flow statement and summary of changes in equity, with the accompanying notes.

DIVIDEND

The Board proposes that no dividend be paid for the 2025/2026 financial year.

Introduction +
Corporate governance +
Financial
Contents
Directors' Report
→ Multi-year overview
→ Definitions
Consolidated accounts
Parent Company accounts
Notes
Signatures
Auditor's Report
Other information +

Multi-year overview

Group, KSEK	2025/26	2024/25	2023/24	2022/23	2021/22	2020/21	2019/20	2018/19	2017/18	2016/17
Net income	478	130	130	546	454	253	341	1,568	726	922
R&D costs	–180,128	–119,504	–96,484	–69,909	–75,567	–56,860	–13,810	–22,359	–29,118	–12,871
Personnel costs	–52,380	–39,224	–31,447	–25,658	–20,259	–16,174	–9,195	–7,891	–7,831	–7,031
Result for the year	–255,593	–169,777	–151,850	–116,073	–103,517	60,046	9,709	–36,610	–43,953	–25,555
Cash flow from operating activities	–195,311	–169,683	–129,181	–110,962	–93,219	–109,468	16,154	–39,185	–41,564	–25,808
Cash and cash equivalents and short-term investments at the balance-sheet date	305,426	277,185	132,366	127,533	159,668	139,376	68,362	56,714	44,112	85,726
Equity ratio, %	67	79	67	82	91	94	81	85	78	88
Result per share, before and after dilution, SEK	–1.8	–1.5	–1.6	–1.5	–1.4	0.9	0.1	–0.5	–0.8	–0.7

2021/22 and onwards pertain to the Group, previous years pertain to the Parent Company.

Parent Company, KSEK	2025/26	2024/25	2023/24	2022/23	2021/22	2020/21	2019/20	2018/19	2017/18	2016/17
Net income	748	525	606	690	506	253	341	1,568	726	922
R&D costs	–180,128	–119,504	–96,484	–69,909	–75,567	–56,860	–13,810	–22,359	–29,118	–12,871
Personnel costs	–52,380	–39,224	–31,447	–25,658	–20,259	–16,174	–9,195	–7,891	–7,831	–7,031
Result for the year	–255,148	–167,225	–160,991	–121,906	–102,381	60,046	9,709	–36,610	–43,953	–25,555
Cash flow from operating activities	–196,093	–168,594	–130,260	–111,819	–93,255	–109,468	16,154	–39,185	–41,564	–25,808
Cash and cash equivalents and short-term investments at the balance-sheet date	304,108	276,443	130,897	124,918	159,145	139,376	68,362	56,714	44,112	85,726
Equity ratio, %	67	80	67	84	92	94	81	85	78	88
Result per share, before and after dilution, SEK	–1.8	–1.5	–1.7	–1.6	–1.3	0.9	0.1	–0.5	–0.8	–0.7

Definitions

Share price	The closing price on August 31.
Equity per share	Equity divided by number of shares at the end of the financial year.
Average number of shares	The weighted average number of shares during the year.
Result per share	Profit/loss for the year divided by average number of shares.
Equity ratio	Equity divided by total assets at the balance-sheet date, expressed as a percentage.

Introduction +
Corporate governance +
Financial
Contents
Directors' Report
Multi-year overview
Definitions
→ Consolidated accounts
Parent Company accounts
Notes
Signatures
Auditor's Report
Other information +

Consolidated income statement

KSEK	Note	Sep 1, 2025 – Aug 31, 2026	Sep 1, 2024 – Aug 31, 2025
Operating income	3		
Net income		478	130
Other operating income		4,205	4,885
Total operating income		**4,682**	**5,015**
Operating expenses			
External research and development costs		–180,128	–119,504
External patent and license costs		–2,761	–3,835
Personnel costs	4	–52,380	–39,224
Other external expenses	5, 6, 7	–18,451	–17,327
Other operating expenses		–1,516	–1,855
Amortization/depreciation and impairment of assets	8, 11.13	–7,023	–6,504
Total operating expenses		**–262,259**	**–188,251**
Operating result		**–257,577**	**–183,236**
Financial items	9		
Gain on sale of financial assets		438	7,465
Impairment of participations in associates	15	–1,264	-
Impairment of participations in other companies	16	–88	–508
Interest income and similar profit items		6,421	10,204
Interest expense and similar loss items		–3,523	–3,702
Total financial items		**1,984**	**13,459**
Result after net financial items		**–255,593**	**–169,777**
Income tax	10	-	-
Result for the period		**–255,593**	**–169,777**



Introduction +
Corporate governance +
Financial
Contents
Directors' Report
Multi-year overview
Definitions
→ Consolidated accounts
Parent Company accounts
Notes
Signatures
Auditor's Report
Other information +

Consolidated balance sheet

KSEK	Note	Aug 31, 2026	Aug 31, 2025
Assets			
Fixed assets			
Intangible assets			
Patents	8	-	-
Tangible assets			
Land and buildings	11	27,429	28,837
Construction in progress	12	-	988
Machinery and inventory	13	19,219	22,877
Financial assets			
Deferred tax		132	193
Participations in associates	15	-	1,264
Other long-term securities	16	9,163	5,984
Other long-term receivables	18	-	91
Total fixed assets		**55,943**	**60,233**
Current assets			
Accounts receivable		57	-
Other receivables		2,650	4,093
Prepaid expenses and accrued income	19	1,177	11,126
Cash and cash equivalents		305,426	277,185
Total current assets		**309,310**	**292,404**
Total assets		**365,253**	**352,638**

KSEK	Note	Aug 31, 2026	Aug 31, 2025
Equity and liabilities			
Equity			
Share capital	20	15,719	13,945
Other contributed capital		1,099,579	884,668
Other equity incl. result for the year		–871,710	–618,615
Total equity		**243,588**	**279,999**
Provisions			
Pensions and other commitments	21	-	113
Other provisions	21	32,509	-
Total provisions		**32,509**	**113**
Long-term liabilities			
Other long-term liabilities	22	55,090	45,043
Total long-term liabilities		**55,090**	**45,043**
Current liabilities			
Trade payables		20,914	11,962
Other current liabilities		6,289	7,916
Accrued expenses and deferred income	23	6,863	7,605
Total current liabilities		**34,066**	**27,483**
Total equity and liabilities		**365,253**	**352,638**

Introduction +
Corporate governance +
Financial
Contents
Directors' Report
Multi-year overview
Definitions
→ Consolidated accounts
Parent Company accounts
Notes
Signatures
Auditor's Report
Other information +

Consolidated cash flow statement

KSEK	Note	Sep 2025 – Aug 2026	Sep 2024 – Aug 2025
Operating activities			
Operating result		–257,577	–183,236
Interest received		5068	8,517
Interest paid		–2837	–2,631
Non-cash flow items			
Amortization/depreciation	11, 13	7,023	6,504
Other non-cash flow items	15, 21	35,033	2,043
Cash flow before changes in working capital		**–213,290**	**–168,803**
Increase (-) decrease (+) accounts receivable		–57	23
Increase (-) decrease (+) other receivables		1,444	–1,388
Increase (-) decrease (+) prepaid expenses/accrued income		9,949	12,924
Increase (+) decrease (-) trade payables		8,953	–4,644
Increase (+) decrease (-) other liabilities		–1,566	–901
Increase (+) decrease (-) accrued expenses/deferred income		–743	–6,894
Total cash flow from operating activities		**–195,311**	**–169,683**

KSEK	Note	Sep 2025 – Aug 2026	Sep 2024 – Aug 2025
Investing activities			
Investments in tangible and intangible assets		–992	–10,048
Investments in financial assets		–4,446	–608
Divestment of financial assets	9	1,133	1,008
Gain on divestment of financial assets		485	7,211
Matured short-term investments		–99,371	19,608
Investment in short-term investments		99,371	-
Cash flow from investing activities		**–3,820**	**17,171**
Financing activities			
New share issue		233,247	315,392
Issue expenses		–16,589	–13,441
Long-term liabilities raised	22	10,047	14,371
Cash flow from financing activities		**226,705**	**316,322**
Cash flow for the period		27,574	163,810
Total cash and cash equivalents at the beginning of the period		277,185	112,758
Effects of currency translation on cash and cash equivalents		667	617
Total cash and cash equivalents at the end of the period		**305,426**	**277,185**

Introduction +
Corporate governance +
Financial
Contents
Directors' Report
Multi-year overview
Definitions
→ Consolidated accounts
Parent Company accounts
Notes
Signatures
Auditor's Report
Other information +

Consolidated change in equity

KSEK	Share capital	Other contributed capital	Other equity incl. result for the year	Total equity
Opening balance September 1, 2024	**10,114**	**586,549**	**–450,742**	**145,920**
Result for the period	-	-	–169,777	–169,777
New share issue	3,831	311,561	-	315,392
Issue expenses	-	–13,441	-	–13,441
Incentive scheme, LTI 2022	-	-	911	911
Incentive scheme, LTI 2024	-	-	875	875
Incentive scheme, Board LTI 2024	-	-	119	119
Closing balance August 31, 2025	**13,945**	**884,668**	**–618,614**	**279,999**
Opening balance September 1, 2025	**13,945**	**884,668**	**–618,614**	**279,999**
Result for the period			–255,593	–255,593
New share issue	1,747	231,500	-	233,247
Issue expenses	-	–16,589	-	–16,589
Incentive scheme, LTI 2022	26	-	573	599
Incentive scheme, LTI 2024	-	-	1,712	1,712
Incentive scheme, Board LTI 2024	-	-	212	212
Closing balance August 31, 2026	**15,719**	**1,099,579**	**–871,710**	**243,588**



Introduction +
Corporate governance +
Financial
Contents
Directors' Report
Multi-year overview
Definitions
Consolidated accounts
→ Parent Company accounts
Notes
Signatures
Auditor's Report
Other information +

Parent Company income statement

KSEK	Note	Sep 1, 2025 – Aug 31, 2026	Sep 1, 2024 – Aug 31, 2025
Operating income	3		
Net income		748	525
Other operating income		4,205	4,885
Total operating income		**4,953**	**5,410**
Operating expenses			
External research and development costs		–180,128	–119,504
External patent and license costs		–2,761	–3,835
Personnel costs	4	–52,380	–39,224
Other external expenses	5, 6, 7	–20,765	–18,080
Other operating expenses		–1,516	–1,855
Amortization/depreciation and impairment of assets	13	–5,066	–4,388
Total operating expenses		**–262,616**	**–186,887**
Operating result		**–257,664**	**–181,477**
Financial items			
Gain on sale of financial asset		438	7,465
Impairment of participations in subsidiaries		-	-
Impairment of participations in associates	15	–1,264	-
Impairment of participations in other companies	16	–88	–508
Interest income and similar profit items	9	6,952	10,998
Interest expense and similar loss items	9	–3,523	–3,702
Total financial items		**2,515**	**14,253**
Result after net financial items		**–255,148**	**–167,225**
Income tax	10	-	-
Result for the period		**–255,148**	**–167,225**



Introduction +
Corporate governance +
Financial
Contents
Directors' Report
Multi-year overview
Definitions
Consolidated accounts
→ Parent Company accounts
Notes
Signatures
Auditor's Report
Other information +

Parent Company balance sheet

KSEK	Note	Aug 31, 2026	Aug 31, 2025
Assets			
Fixed assets			
Intangible assets			
Patents	8	-	-
Tangible assets			
Construction in progress	12	-	700
Machinery and inventory	13	18,959	22,562
Financial assets			
Shares in subsidiaries	14	16,291	16,291
Long-term receivables from subsidiaries	17	15,000	15,000
Participations in associates	15	-	1,264
Other long-term securities	16	9,163	5,984
Other long-term receivables	18	0	91
Total fixed assets		**59,413**	**61,892**
Current assets			
Accounts receivable		41	-
Receivables from Group companies		238	809
Other receivables		2,517	3,972
Prepaid expenses and accrued income	19	1,155	11,095
Cash and cash equivalents and short-term investments		304,108	276,443
Total current assets		**308,059**	**292,319**
Total assets		**367,472**	**354,211**

KSEK	Note	Aug 31, 2026	Aug 31, 2025
Equity and liabilities			
Equity			
Restricted equity			
Share capital	20	15,719	13,945
Statutory reserve		200	200
Non-restricted equity			
Share premium reserve		1,099,379	884,468
Retained earnings		–613,886	–449,158
Result for the period		–255,148	–167,225
TOTAL EQUITY		**246,264**	**282,230**
Provisions			
Pensions and other commitments	21	-	113
Other provisions	21	32,509	-
Total provisions		**32,509**	**113**
Long-term liabilities			
Other long-term liabilities	22	55,090	45,043
Total long-term liabilities		**55,090**	**45,043**
Current liabilities			
Trade payables		20,870	11,597
Other current liabilities		5,946	7,622
Liabilities to Group companies		-	-
Accrued expenses and deferred income	23	6,793	7,605
Total current liabilities		**33,609**	**26,824**
Total equity and liabilities		**367,472**	**354,211**

Introduction +
Corporate governance +
Financial
Contents
Directors' Report
Multi-year overview
Definitions
Consolidated accounts
→ Parent Company accounts
Notes
Signatures
Auditor's Report
Other information +

Parent Company cash flow statement

KSEK	Note	Sep 2025 – Aug 2026	Sep 2024 – Aug 2025
Operating activities			
Operating result		–257,664	–181,477
Interest received		5,599	9,310
Interest paid		–2,837	–2,631
Non-cash flow items			
Amortization/depreciation	13	5,089	4,388
Other non-cash flow items	15, 21	35,010	2,043
Cash flow before changes in working capital		**–214,803**	**–168,367**
Increase (-) decrease (+) accounts receivable		–41	-
Increase (-) decrease (+) other receivables		1,454	–1,384
Increase (-) decrease (+) prepaid expenses/accrued income		10,512	13,771
Increase (+) decrease (-) trade payables		9,273	–4,814
Increase (+) decrease (-) other liabilities		–1,676	–906
Increase (+) decrease (-) accrued expenses/deferred income		–813	–6,894
Total cash flow from operating activities		**–196,093**	**–168,594**

KSEK	Note	Sep 2025 – Aug 2026	Sep 2024 – Aug 2025
Investing activities			
Investments in tangible and intangible assets	12, 13	–785	–8,411
Investments in financial assets	14, 15	–4,446	–5,608
Dissolution of loans to subsidiaries		-	3,000
Divestment of financial assets		1,133	1,008
Gain on divestment of financial assets		485	7,211
Matured short-term investments		-	19,608
Investment in short-term investments		-	–
Cash flow from investing activities		**–3,614**	**16,809**
Financing activities			
New share issue		233,247	315,392
Issue expenses		–16,589	–13,441
Long-term liabilities raised	22	10,047	14,371
Cash flow from financing activities		**226,705**	**316,322**
Cash flow for the period		26,998	164,536
Total cash and cash equivalents at the beginning of the period		276,443	111,289
Effects of currency translation on cash and cash equivalents		667	618
Total cash and cash equivalents at the end of the period		**304,108**	**276,443**

Introduction +
Corporate governance +
Financial
Contents
Directors' Report
Multi-year overview
Definitions
Consolidated accounts
→ Parent Company accounts
Notes
Signatures
Auditor's Report
Other information +

Parent Company change in equity

KSEK	Share capital	Statutory reserve	Share premium reserve	Other non-restricted equity	Total equity
Opening balance September 1, 2024	**10,114**	**200**	**586,349**	**–451,064**	**145,599**
Result for the period	-	-	-	–167,225	–167,225
New share issue	3,831	-	311,561	-	315,392
Issue expenses	-	-	–13,441	-	–13,441
Incentive scheme, LTI 2022	-	-	-	911	911
Incentive scheme, LTI 2024	-	-	-	875	875
Incentive scheme, Board LTI 2024	-	-	-	119	119
Closing balance August 31, 2025	**13,945**	**200**	**884,469**	**–616,384**	**282,230**
Opening balance September 1, 2025	**13,945**	**200**	**884,469**	**–616,384**	**282,230**
Result for the period	-	-	-	–255,148	–255,148
New share issue	1,747	-	231,500	-	233,247
Issue expenses	-	-	–16,589	-	–16,589
Incentive scheme, LTI 2022	26	-	-	573	599
Incentive scheme, LTI 2024	-	-	-	1,924	1,924
Closing balance August 31, 2026	**15,719**	**200**	**1,099,379**	**–869,034**	**246,264**

Introduction +
Corporate governance +
Financial
Contents
Directors' Report
Multi-year overview
Definitions
Consolidated accounts
Parent Company accounts
→ Notes
Signatures
Auditor's Report
Other information +

Notes

NOTE 1

Recognition and measurement principles

The financial statements have been prepared in accordance with the Swedish Annual Accounts Act and the Swedish Accounting Standards Board's BFNAR 2012:10 Annual report and consolidated financial statements (K3). All amounts are stated in Swedish kronor (SEK) unless otherwise indicated.

CONSOLIDATED FINANCIAL STATEMENTS

The consolidated financial statements encompass the Parent Company Diamyd Medical AB and the companies over which the Parent Company has a direct or indirect controlling influence (subsidiary). Controlling influence entails a right to formulate another corporate financial and operating strategy to obtain economic benefits. When assessing whether a controlling influence exists, account should be taken of financial instruments that may carry voting rights that can be utilized without delay or converted into equity instruments that carry voting rights. Consideration should also be taken of whether the Company has the ability to govern operations through an agent. Controlling influence normally exists when the Parent Company directly or indirectly holds shares that represent more than 50% of the votes. A subsidiary's revenues and expenses are included in the consolidated financial statements from the date of the acquisition until the date when the Parent Company no longer has a controlling influence over the subsidiary. All intra-Group transactions, dealings and unrealized gains or losses relating to intra-Group transactions were eliminated when preparing the consolidated financial statements.

Revenue recognition
Sales of goods or services are recognized when the risks and rewards of ownership have been transferred from the seller to the buyer in accordance with the terms of sale. The sale is recognized less sales tax and discounts.

Public funding
Public funding is recognized at fair value when there is reasonable certainty that the funding will be received and that the Group will meet the conditions tied to the funding. Before the conditions for recognition as revenues are met, funding received is recognized as a liability.

Associates
Associates are consolidated in the consolidated financial statements by applying the equity method, which means shares in the associate are initially measured at cost in the consolidated financial statements, and are then adjusted to reflect the Company's share of the associate's results with a delay of one quarter. The Parent Company recognizes associates at cost less any impairment losses. Any dividends are recognized as financial income. Impairment tests are carried out on an annual basis.

Intangible assets
Intangible assets refer to license rights, acquired directly or through business combinations. Patent license fees are recognized as an asset if the licenses pertain to a controllable asset deemed commercially viable. This also applies if the license rights are deemed transferable at their fair value. The licenses are amortized on a straight-line basis over their estimated useful life from the date they become usable. Proprietary patent rights, technology rights, trademarks and other similar assets are not assigned any value. No development costs meet the criteria for capitalization, which means that all research and development costs are expensed as incurred.

Financial instruments
A financial asset or liability is recognized on the balance sheet in accordance with the contractual terms of the instrument. A financial asset is derecognized when the contractual rights to the cash flows from the asset have expired or are forfeited. A financial liability (or part of the liability) is derecognized when the obligation specified in the contract is discharged, canceled or expires. Current assets and current liabilities are initially measured at cost. Long-term receivables are initially measured at amortized cost. Current assets are subsequently measured using the lowest value principle, which means the lower of cost or net realizable value at the balance-sheet date. Current liabilities are measured at their nominal amounts. The Company assesses the fair values of financial assets on an annual basis to determine whether there is any indication that an asset may be impaired. The assessment is made on a case-by-case basis.

Leases
Leases are classified as finance or operating leases. A finance lease exists when the economic risks and rewards incidental to ownership are substantially transferred to the lessee. In other cases, operating leases exist. In the case of operating leases, the lease payment is expensed over the term of the lease on a time-of-use basis.

Introduction +
Corporate governance +
Financial
Contents
Directors' Report
Multi-year overview
Definitions
Consolidated accounts
Parent Company accounts
→ Notes
Signatures
Auditor's Report
Other information +

NOTE 1, CONT.

When an agreement is entered into, the Company assesses whether the contract is a lease. The lease term consists of the non-cancellable period, taking into account any extension options if it is deemed reasonably certain on the commencement date that these will be utilized. Lease payments for leases with a lease term of 12 months or less or when the underlying asset is of low-value are charged to profit or loss on a straight-line basis over the lease term.

Income tax
Current tax is income tax for the current financial year, pertaining to taxable profit for the year. Deferred tax assets related to loss carryforwards or other future tax losses are only recognized to the extent it is probable that the tax loss can be recovered against future taxable profit.

Provisions
Provisions are recognized when there is a present obligation (legal or constructive) resulting from a past event where it is probable that an outflow of resources will be required to settle the obligation. Provisions are reviewed annually.

Employee benefits
Employee benefits in the form of salaries, paid vacation and sick leave, and pensions are recognized as they are earned. Pensions and other post-employment benefits are classified as either defined-contribution or defined-benefit pension schemes. The Company has defined-contribution pension schemes for which it pays fixed fees to an insurance company and has no obligation to pay additional fees. All of these pension costs are charged to operating profit. The Company also has one defined-benefit pension scheme related to a former employee. The premium payments ceased when employment was terminated, and there is no obligation to make any further payments. Therefore, no actuarial assumptions are required to calculate pension obligations or costs, nor is it possible to recognize actuarial gains or losses.

Receivables and liabilities in foreign currency
Receivables and liabilities in foreign currency are translated using the applicable exchange rates at the balance-sheet date. Currency gains and losses arising from the payment of such transactions, and from the translation of monetary assets and liabilities in foreign currency using the closing rate, are recognized in profit or loss. All exchange-rate differences are recognized in profit or loss.

Depreciation/amortization of fixed assets
Fixed assets are depreciated/amortized using the straight-line method over their estimated useful life. Depreciation/amortization according to plan has been calculated using the original cost and depreciation/amortization rates based on the estimated useful life of the assets. The useful life of the fixed assets is tested annually. Patents are amortized over five years. Machinery and equipment are depreciated over three to ten years and buildings up to 50 years.

Cash flow statement
The cash flow statement has been prepared using the indirect method. The cash flow reported only includes inflows and outflows of cash transactions. In addition to cash and bank balances, the classification of cash and cash equivalents also includes short-term investments, such as commercial papers with a maturity date of three months or less from their date of issue, that can easily be converted into a known amount and are only exposed to a negligible risk of value fluctuation.

ACCOUNTING POLICIES FOR THE PARENT COMPANY

Subsidiaries
Shares in subsidiaries are recognized at cost adjusted for any appreciation or impairment. Dividends from subsidiaries are recognized as income when the right to receive a dividend is deemed certain and can be reliably calculated.

Introduction +
Corporate governance +
Financial
Contents
Directors' Report
Multi-year overview
Definitions
Consolidated accounts
Parent Company accounts
→ Notes
Signatures
Auditor's Report
Other information +

NOTE 2

Estimates and judgments

The financial statements have been prepared in accordance with BFNAR 2012:10 (K3), which requires management to make estimates and assumptions that affect the application of the Company's accounting policies and the amounts recognized in the financial statements. The actual results may differ from these estimates and judgments, which is why they are continuously evaluated. The effect of a change in an accounting estimate is recognized in the period in which the change took place if the change affects that period only, or in the period in which the change took place and future periods if the change affects both. The judgments made by management with the most significant effects on the amounts recognized in the financial statements and that could have a material effect on future periods are set out below.

INTANGIBLE ASSETS

Patent license fees are recognized as an asset if these could be regarded as a controllable asset deemed commercially viable.

TANGIBLE ASSETS

In conjunction with the acquisition of the Formen 12 property in Umeå, which is owned by the subsidiary Diamyd Biomanufacturing AB, its building was divided into components for accounting purposes. The division was based on the building's condition and use, and an assessment was conducted to decide on the useful life for each component, which was used as a basis for the depreciation periods.

An external valuation was carried out in the previous financial year of the Umeå Formen 12 property to assess the market value of the valuation object.

FINANCIAL ASSETS

Other long-term securities consist of shares in NextCell Pharma AB and Waterise B.V. Impairment tests are conducted on an ongoing basis.

ACCRUED EXPENSES

Other accrued expenses mainly consist of costs to contract research organizations for providing clinical trial services. The amount is based on an assessment of agreements and completed parts of assignments.

NOTE 3

Operating income

Group, KSEK	2025/26	2024/25
Sales of GAD for research purposes	458	105
Operating exchange gains	432	291
Accrued funding received	3,773	4,594
Other income	20	25
Total	**4,682**	**5,015**

Parent Company, KSEK	2025/26	2024/25
Sales of GAD for research purposes	458	105
Operating exchange gains	432	291
Accrued funding received	3,773	4,594
Other income	5	-
Intra-Group invoicing	285	420
Total	**4,953**	**5,410**

Accrued funding received related to eligible costs for VINNOVA-financed projects. There are no contingent assets or contingent liabilities in connection with this funding.

Introduction +
Corporate governance +
Financial
Contents
Directors' Report
Multi-year overview
Definitions
Consolidated accounts
Parent Company accounts
→ Notes
Signatures
Auditor's Report
Other information +

NOTE 4

Personnel costs

Average no. of employees	2025/26	2024/25
Of whom women	29	23
Of whom men	13	10
Total	**42**	**33**

Gender representation on Board and Management Team	Aug 31, 2026 Women	Aug 31, 2026 Men	Aug 31, 2025 Women	Aug 31, 2025 Men
Board of Directors	3	4	3	4
Management Team	2	5	2	3
Total	**5**	**9**	**5**	**7**

Salaries, other compensation and social security contributions 2025/26 KSEK	Salary/fees and other compensation	Pension costs	Social security contributions	Incentive scheme	Total
Erik Nerpin, Chairman	153	-	48	-	201
Anders Essen-Möller, Board member & CEO[1)]	1,669	-	89	-	1,758
Maria-Teresa Essen-Möller, Board member	125	-	39	-	164
Torbjörn Bäckström, Board member	125	-	13	-	138
Mark Atkinson, Board member[3)]	125	-	0	-	125
Karin Hehenberger, Board member	125	-	0	-	125
Karin Rosén, Board member	125	-	0	-	125
Ulf Hannelius, former President and CEO	2,684	584	307	-	3,575
Others senior management	6,644	1,046	1,142	-	8,832
Other employees	25,232	2,600	5,780	-	33,613
Incentive scheme, LTI 2022	-	-	-	573	573
Incentive scheme, LTI 2024[2)]	-	-	-	1,712	1,712
Incentive scheme, Board LTI 2024[3)]	-	-	-	212	212
Total	**36,855**	**4,231**	**7,370**	**2,497**	**50,953**

Salaries, other compensation and social security contributions 2024/25 KSEK	Salary/fees and other compensation	Pension costs	Social security contributions	Incentive scheme	Total
Anders Essen-Möller, Chairman	1,632	-	18	-	1,650
Erik Nerpin, Vice Chairman	1,900	-	47	-	1,947
Maria-Teresa Essen-Möller, Board member	125	-	39	-	164
Torbjörn Bäckström, Board member	125	-	13	-	138
Mark Atkinson, Board member	175	-	0	-	175
Karin Hehenberger, Board member	125	-	0	-	125
Karin Rosén, Board member	125	-	0	-	125
Ulf Hannelius, President and CEO	2,495	612	285	-	3,391
Others senior management	5,045	966	913	-	6,924
Other employees	18,971	2,055	2,810	-	23,836
Incentive scheme, LTI 2022	-	-	-	911	911
Incentive scheme, LTI 2024	-	-	-	875	875
Incentive scheme, Board LTI 2024	-	-	-	119	119
Total	**30,718**	**3,632**	**4,125**	**1,905**	**40,380**

1) Of the amount, 172 refers to Board fees, 794 to consulting fees and 703 to CEO salary. See also Note 5.

2) At August 31, 2026, the Company had granted 44 participants performance share rights in accordance with LTI 2024. A total of 440,000 performance share rights have been granted. The LTI 2024 rights were valued on the allotment date at the fair value of the allotted equity instrument. The personnel costs were based on the allotment value, simulated using the Monte Carlo method.

3) At August 31, 2026, the Company had granted 6 participants performance share rights in accordance with LTI 2024. A total of 60,000 performance share rights have been granted. The Board LTI 2024 rights were valued on the allotment date at the fair value of the allotted equity instrument. The personnel costs were based on the allotment value, simulated using the Monte Carlo method.

Introduction +
Corporate governance +
Financial
Contents
Directors' Report
Multi-year overview
Definitions
Consolidated accounts
Parent Company accounts
→ Notes
Signatures
Auditor's Report
Other information +

NOTE 5

Related-party transactions

During the period, companies represented by a related party to the principal owner and Board member and CEO Anders Essen-Möller were engaged on a consultancy basis. Total consulting fees and salaries paid to related parties amounted to KSEK 2,267 (2,229).

Executive Board member and CEO, Anders Essen-Möller was paid an amount of KSEK 793 (3,257) through a company owned by Essen-Möller.

The Arm's Length principle was applied to pricing.

Group, KSEK	2025/26	2024/25
Consulting fees and salaries to related parties	2,267	2,229
Consulting fees to Board members	794	3,257

Parent Company, KSEK	2025/26	2024/25
Consulting fees and salaries to related parties	2,267	2,229
Consulting fees to Board members	794	3,257

NOTE 6

Auditor's fees

Group, KSEK	2025/26	2024/25
BDO Mälardalen AB		
Audit assignments	512	568
Audit business in addition to audit assignments	96	14
Other advisory services	4	40
Total	**612**	**622**

Parent Company, KSEK	2025/26	2024/25
BDO Mälardalen AB		
Audit assignments	512	568
Audit business in addition to audit assignments	96	14
Other advisory services	4	40
Total	**612**	**622**

NOTE 7

Leases

Group, KSEK	2025/26	2024/25
Lease payments, incl. rent during the year	1,425	998
Future lease payments incl. rent are due for payment as follows:		
Within 1 year	1,111	1,388
Within 2–5 years	76	1,910
Total	**1,187**	**3,298**

Parent Company, KSEK	2025/26	2024/25
Lease payments, incl. rent during the year	4,285	3,714
Future lease payments incl. rent are due for payment as follows:		
Within 1 year	3,971	4,104
Within 2–5 years	11,516	12,775
Within 6–10 years	5,720	8,149
Total	**21,207**	**25,028**

At August 31, 2026, the Parent Company had two rental agreements for office premises in Stockholm.

One rental agreement with a remaining term of one year and one month, and one small office premises with a remaining term of five months.

Diamyd Medical has a rental agreement with Diamyd Biomanufacturing AB for office and lab premises in Umeå with a remaining term extending until August 31, 2033.

Introduction +
Corporate governance +
Financial
Contents
Directors' Report
Multi-year overview
Definitions
Consolidated accounts
Parent Company accounts
→ Notes
Signatures
Auditor's Report
Other information +

NOTE 8

Patents

Group, KSEK	Aug 31, 2026	Aug 31, 2025
Opening balance	11,076	11,076
Closing accumulated balance	11,076	11,076
Closing accumulated amortization	–11,076	–11,076
Closing carrying amount	-	-

Parent Company, KSEK	Aug 31, 2026	Aug 31, 2025
Opening balance	11,076	11,076
Closing accumulated balance	11,076	11,076
Closing accumulated amortization	–11,076	–11,076
Closing carrying amount	-	-

NOTE 9

Financial items

Financial income

Group, KSEK	2025/26	2024/25
Gain on sale of securities	438	7,465
Interest income	2,928	2,344
Exchange gains	3,493	7,860
Total	**6,859**	**17,669**

Parent Company, KSEK	2025/26	2024/25
Gain on sale of securities	438	7,465
Interest income	3,459	3,137
Exchange gains	3,493	7,860
Total	**7,391**	**18,462**

Financial costs

Group, KSEK	2025/26	2024/25
Impairment of holdings in participations in other companies	–88	–508
Impairment of participations in associates	–1,264	-
Interest expense	–4	-
Exchange losses	**–3,519**	**–3,702**
Total	**–4,875**	**–4,210**

Parent Company, KSEK	2025/26	2024/25
Impairment of holdings in participations in other companies	–88	-
Impairment of holdings in participations in other companies	–1,264	–508
Interest expense	–4	-
Exchange losses	–3,519	–3,702
Total	**–4,875**	**–4,210**

NOTE 10

Income tax

Group, KSEK	2025/26	2024/25
Current tax		
Reconciliation of effective tax		
Profit/loss before tax	–255,593	–169,777
Tax at applicable tax rate	52,652	34,974
Tax effect of:		
Non-deductible expenses	–375	–249
Non-taxable income	91	1,573
Other unrecognized expenses[1)]	3,417	2,769
Loss carryforwards incurred during the year for which no tax assets are recognized	55,785	39,067
Loss carryforwards utilized during the year	-	-
Tax expense	-	-

Parent Company, KSEK	2025/26	2024/25
Current tax		
Reconciliation of effective tax		
Profit/loss before tax	–255,148	–167,225
Tax at applicable tax rate	52,560	34,448
Tax effect of:		
Non-deductible expenses	–375	–249
Non-taxable income	91	1,572
Other unrecognized expenses[1)]	3,417	2,769
Capital gain on divestments	–186	–119
Loss carryforwards incurred during the year for which no tax assets are recognized	55,507	38,422
Loss carryforwards utilized during the year	-	-
Tax expense	-	-

1) Other unrecognized expenses relate to issue expenses in connection with new share issues carried out during the financial year

Introduction +
Corporate governance +
Financial
Contents
Directors' Report
Multi-year overview
Definitions
Consolidated accounts
Parent Company accounts
→ Notes
Signatures
Auditor's Report
Other information +

NOTE 11

Land and buildings

Group, KSEK	Aug 31, 2026	Aug 31, 2025
Land and buildings		
Opening balance	41,468	39,836
Property purchases	-	-
Investments in existing properties	-	1,219
Reclassification	494	413
Closing balance	**41,961**	**41,468**
Opening depreciation land and buildings	–12,630	–10,545
Depreciation for the year land and buildings	–1,902	–2,085
Impairment for the year	-	-
Closing accumulated depreciation	**–14,532**	**–12,630**
Closing carrying amount land and buildings	**27,429**	**28,837**

NOTE 12

Construction in progress

Group, KSEK	Aug 31, 2026	Aug 31, 2025
Construction in progress		
Opening balance	988	413
Construction in progress purchases	305	988
Reclassification	–1,293	–413
Closing carrying amount construction in progress	**0**	**988**

Parent Company, KSEK	Aug 31, 2026	Aug 31, 2025
Construction in progress		
Opening balance	700	-
Construction in progress purchases	99	700
Reclassification	–799	-
Closing carrying amount construction in progress	**0**	**700**

NOTE 13

Machinery and equipment

Group, KSEK	Aug 31, 2026	Aug 31, 2025
Machinery and equipment		
Opening balance	37,207	29,673
Purchases	687	7,842
Disposals machinery and equipment	–28	–308
Reclassifications	799	-
Closing balance	**38,665**	**37,207**
Opening depreciation machinery and equipment	–14,329	–10,020
Depreciation for the year machinery and equipment	–5,121	–4,419
Disposals machinery and equipment	6	110
Closing accumulated depreciation	**–19,444**	**–14,329**
Closing carrying amount machinery and equipment	**19,219**	**22,877**

Parent Company, KSEK	Aug 31, 2026	Aug 31, 2025
Machinery and equipment		
Opening balance	38,192	30,789
Purchases	687	7,711
Disposals machinery and equipment	–28	–308
Reclassifications	799	-
Closing balance	**39,650**	**38,192**
Opening depreciation machinery and equipment	–15,630	–11,351
Depreciation for the year machinery and equipment	–5,066	–4,388
Disposals machinery and equipment	6	110
Closing accumulated depreciation	**–20,691**	**–15,630**
Closing carrying amount machinery and equipment	**18,959**	**22,562**

Introduction +
Corporate governance +
Financial
Contents
Directors' Report
Multi-year overview
Definitions
Consolidated accounts
Parent Company accounts
→ Notes
Signatures
Auditor's Report
Other information +

NOTE 14

Participations in subsidiaries

Parent Company, KSEK Company	Corp. Reg. No.	Registered office	Votes, %	Share of capital, %	No. of shares	Aug 31, 2026 Carrying amount	Aug 31, 2025 Carrying amount
Diamyd Biomanufacturing AB	559041-0931	Stockholm, Region Stockholm	100.0	100.0	500	16,291	16,291
Closing accumulated balance					500	16,291	16,291
Closing carrying amount					**500**	**16,291**	**16,291**

Information about equity and earnings for Diamyd Biomanufacturing AB (KSEK)	Aug 31, 2025	Aug 31, 2024
Equity according to most recently adopted financial statements	7,441	4,487
Result according to most recently adopted financial statements	–2,047	–571

NOTE 15

Participations in associates

Group, KSEK	Aug 31, 2026	Aug 31, 2025
Opening balance	1,264	1,264
Participations acquired in associates during the year	-	-
Impairment of participations in associates during the year	–1,264	-
Adjustment of share in profits using the equity method	-	-
Adjustment of previously reversed impairment in the Group	-	-
Reclassification to Other long-term securities	-	-
Carrying amount at year end	**0**	**1,264**

Parent Company, KSEK	Aug 31, 2026	Aug 31, 2025
Opening balance	1,264	1,264
Participations acquired in associates during the year	-	-
Impairment of participations in associates during the year	–1,264	-
Reclassification to Other long-term securities	-	-
Carrying amount at year end	**0**	**1,264**

The previous holding in MainlyAI AB has been written off in its entirety due to bankruptcy as of June 2026.

Introduction +
Corporate governance +
Financial
Contents
Directors' Report
Multi-year overview
Definitions
Consolidated accounts
Parent Company accounts
→ Notes
Signatures
Auditor's Report
Other information +

NOTE 16

Other long-term securities

Group, KSEK Company	Corp. Reg. No.	Registered office	Votes, %	Share of capital, %	No. of shares	Aug 31, 2026 Carrying amount	Aug 31, 2025 Carrying amount
NextCell Pharma AB	556965-8361	Huddinge, Region Stockholm	3.6	3.6	4,492,051	4,717	5,984
Waterise B.V.	88419398[1)]	Amsterdam, Netherlands	1.2	1.2	107,291	4,446	-

Parent Company, KSEK Company	Corp. Reg. No.	Registered office	Votes, %	Share of capital, %	No. of shares	Aug 31, 2026 Carrying amount	Aug 31, 2025 Carrying amount
NextCell Pharma AB	556965-8361	Huddinge, Region Stockholm	3.6	3.6	4,492,051	4,717	5,984
Waterise B.V.	88419398[1)]	Amsterdam, Netherlands	1.2	1.2	107,291	4,446	-

Information about equity and earnings for NextCell Pharma AB	2025-12-31	Aug 31, 2024
Equity according to most recently adopted financial statements	64,093	67,599
Result according to most recently adopted financial statements	–37,440	–41,960

1) Trade register number

NOTE 17

Long-term receivables from subsidiaries

Parent Company, KSEK	Aug 31, 2026	Aug 31, 2025
Opening balance	15,000	18,000
Loans to Diamyd Biomanufacturing AB	0	–3,000
Closing accumulated balance	**15,000**	**15,000**
Closing carrying amount	**15,000**	**15,000**

NOTE 18

Other long-term receivables

Group, KSEK	Aug 31, 2026	Aug 31, 2025
Opening balance	91	338
Settlement	–91	–247
Closing accumulated balance	**0**	**91**
Closing carrying amount	**0**	**91**

Parent Company, KSEK	Aug 31, 2026	Aug 31, 2025
Opening balance	91	338
Settlement	–91	–247
Closing accumulated balance	**0**	**91**
Closing carrying amount	**0**	**91**

The amount consists of a pension provision in an endowment policy.

Introduction +
Corporate governance +
Financial
Contents
Directors' Report
Multi-year overview
Definitions
Consolidated accounts
Parent Company accounts
→ Notes
Signatures
Auditor's Report
Other information +

NOTE 19

Prepaid expenses and accrued income

Group, KSEK	2025/26	2025/26
Prepaid rent	41	41
Prepaid insurance premiums	195	288
Prepaid research and development costs	177	9,403
Other prepaid expenses	612	849
Other accrued income	152	545
Total	**1,177**	**11,126**

Parent Company, KSEK	2025/26	2025/26
Prepaid rent	41	41
Prepaid insurance premiums	195	280
Prepaid research and development costs	177	9,403
Other prepaid expenses	590	827
Other accrued income	152	544
Total	**1,155**	**11,095**

NOTE 20

Share capital

For a specification of the Parent Company's changes in equity, refer to *"Change in equity"* on page 32.

At August 31, 2026, the number of shares in Diamyd Medical AB comprised 151,481,380 Class B shares (one-tenth of a vote per share) and 3,503,120 Class A shares (one vote per share). At the end of the financial year, Diamyd Medical AB's share capital amounted to SEK 15,718,722 (13,945,395).

The (rounded) quotient value was 0.1014 (0.1014). All shares issued are fully paid.

NOTE 21

Provisions

Group, KSEK	Aug 31, 2026	Aug 31, 2025
Opening balance	113	420
Withdrawal	–113	–307
Other provisions	32,509	-
Closing accumulated balance	**32,509**	**113**
Closing carrying amount	**32,509**	**113**

Parent Company, KSEK	Aug 31, 2026	Aug 31, 2025
Opening balance	113	420
Withdrawal	–113	–307
Other provisions	32,509	-
Closing accumulated balance	**32,509**	**113**
Closing carrying amount	**32,509**	**113**

Other provisions consist of close-down costs related to DIAGNODE-3.

NOTE 22

Long-term liabilities

Group, KSEK	Aug 31, 2026	Aug 31, 2025
Opening balance	45,043	30,672
Other long-term liabilities, Breakthrough T1D	10,047	14,371
Closing carrying amount	**55,090**	**45,043**

Parent Company, KSEK	Aug 31, 2026	Aug 31, 2025
Opening balance	45,043	30,672
Other long-term liabilities, Breakthrough T1D	10,047	14,371
Closing carrying amount	**55,090**	**45,043**

Diamyd Medical receives financing within the partnership with Breakthrough T1D (previously JDRF), when certain milestones have been reached. During the 2025/2026 financial year, Diamyd Medical passed one such milestone and received a total of MSEK 10. If Diamyd Medical obtains commercial approval for Diamyd and sales of the drug are commercially successful, Breakthrough T1D will receive limited royalties. As a result of Diamyd Medical's commitments pertaining to future royalties, payments from Breakthrough T1D are recognized as long-term liabilities.

Introduction +
Corporate governance +
Financial
Contents
Directors' Report
Multi-year overview
Definitions
Consolidated accounts
Parent Company accounts
→ Notes
Signatures
Auditor's Report
Other information +

NOTE 23

Accrued expenses and deferred income

Group, KSEK	2025/26	2024/25
Accrued vacation pay	4,050	3,037
Accrued social security contributions	1,243	954
Accrued salaries	-	-
Accrued research costs	644	1,264
Other accrued expenses	926	2,349
Total	**6,863**	**7,605**

Parent Company, KSEK	2025/26	2024/25
Accrued vacation pay	4,050	3,037
Accrued social security contributions	1,243	954
Accrued salaries	-	-
Accrued research costs	644	1,264
Other accrued expenses	856	2,349
Total	**6,793**	**7,605**

NOTE 24

Pledged assets and contingent liabilities

There are no pledged assets or contingent liabilities.

NOTE 25

Significant events after the end of the financial year

No significant events occurred after the end of the financial year.

NOTE 26

Appropriation of profit/loss

Parent Company
The following profits are at the disposal of the Annual General Meeting

	SEK
Share premium reserve	1,099,379,151
Retained earnings	–613,885,931
Result for the year	–255,147,828
	230,345,392
The Board and CEO propose that the following profits be carried forward SEK	**230,345,392**

Introduction +
Corporate governance +
Financial
Contents
Directors' Report
Multi-year overview
Definitions
Consolidated accounts
Parent Company accounts
Notes
→ Signatures
Auditor's Report
Other information +

Signatures of the Board of Directors and Chief Executive Officer

The Group's income statements and balance sheets will be submitted to the Annual General Meeting on December 3, 2026 for adoption. The Board of Directors and the Chief Executive Officer provide their assurance that the Annual Report has been prepared in accordance with generally accepted accounting policies and presents a true and fair view of the operations, financial position and earnings, and that the Directors' Report presents a true and fair view of the Group's and Parent Company's operations, financial position and earnings and describes the material risks and uncertainties faced by the Group and Parent Company.

The contents of the annual accounts were finalized on November 3, 2026.

Stockholm, November 12, 2026.

Anders Essen-Möller
Board member and CEO

Erik Nerpin
Chairman

Maria-Teresa Essen-Möller
Board member

Torbjörn Bäckström
Board member

Mark A. Atkinson
Board member

Karin Hehenberger
Board member

Karin Rosén
Board member

Our Auditor's Report was submitted on November 12, 2026.

BDO Mälardalen AB

Johan Pharmanson
Authorized Public Accountant

Introduction +
Corporate governance +
Financial
Contents
Directors' Report
Multi-year overview
Definitions
Consolidated accounts
Parent Company accounts
Notes
Signatures
→ Auditor's Report
Other information +

Auditor's Report

To the general meeting of the shareholders of Diamyd Medical Aktiebolag Corporate identity number 556242-3797

REPORT ON THE ANNUAL ACCOUNTS AND CONSOLIDATED ACCOUNTS

Opinions

We have audited the annual accounts and consolidated accounts of Diamyd Medical Aktiebolag for the financial year 2025-09-01 – 2026-08-31. The annual accounts and consolidated accounts of the company are included on pages 17–44 in this document.

In our opinion, the annual accounts and consolidated accounts have been prepared in accordance with the Annual Accounts Act and present fairly, in all material respects, the financial position of parent company and the group as of 31 August 2026 and their financial performance and cash flows for the year then ended in accordance with the Annual Accounts Act. The statutory administration report is consistent with the other parts of the annual accounts and consolidated accounts.

We therefore recommend that the general meeting of shareholders adopts the income statement and balance sheet for the parent company and the group.

Basis for Opinions

We conducted our audit in accordance with International Standards on Auditing (ISA) and generally accepted auditing standards in Sweden. Our responsibilities under those standards are further described in the "Auditor's Responsibilities" section. We are independent of the parent company and the group in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled our ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinions.

Other information than the annual accounts and consolidated accounts

This document also contains other information than the annual accounts and consolidated accounts and is found on pages 1–16.

Our opinion on the annual accounts and consolidated accounts does not cover this other information and we do not express any form of assurance conclusion regarding this other information.

In connection with our audit of the annual accounts and consolidated accounts, our responsibility is to read the information identified above and consider whether the information is materially inconsistent with the annual accounts and consolidated accounts. In this procedure we also take into account our knowledge otherwise obtained in the audit and assess whether the information otherwise appears to be materially misstated.

If we, based on the work performed concerning this information, conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Board of Directors and the Managing Director

The Board of Directors and the Managing Director are responsible for the preparation of the annual accounts and consolidated accounts and that they give a fair presentation in accordance with the Annual Accounts Act. The Board of Directors and the Managing Director are also responsible for such internal control as they determine is necessary to enable the preparation of annual accounts and consolidated accounts that are free from material misstatement, whether due to fraud or error.

In preparing the annual accounts and consolidated accounts, the Board of Directors and the Managing Director are responsible for the assessment of the company's and the group's ability to continue as a going concern. They disclose, as applicable, matters related to going concern and using the going concern basis of accounting. The going concern basis of accounting is however not applied if the Board of Directors and the Managing Director intends to liquidate the company, to cease operations, or has no realistic alternative but to do so.

Auditor's responsibility

Our objectives are to obtain reasonable assurance about whether the annual accounts and consolidated accounts as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinions. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs and generally accepted auditing standards in Sweden will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual accounts and consolidated accounts.

A further description of our responsibilities for the audit of the annual accounts and the consolidated financial statements is available on the Swedish Inspectorate of Auditors' website: www.revisorsinspektionen.se/revisornsansvar. This description comprises part of the auditor's report.

REPORT ON OTHER LEGAL AND REGULATORY REQUIREMENTS

Opinions

In addition to our audit of the annual accounts and consolidated accounts, we have also audited the administration of the Board of Directors and the Managing

Introduction +
Corporate governance +
Financial
Contents
Directors' Report
Multi-year overview
Definitions
Consolidated accounts
Parent Company accounts
Notes
Signatures
→ Auditor's Report
Other information +

Director of Diamyd Medical Aktiebolag for the financial year 2025-09-01 – 2026-08-31 and the proposed appropriations of the company's profit or loss.

We recommend to the general meeting of shareholders that the profit be appropriated in accordance with the proposal in the statutory administration report and that the members of the Board of Directors and the Managing Director be discharged from liability for the financial year.

Basis for Opinions

We conducted the audit in accordance with generally accepted auditing standards in Sweden. Our responsibilities under those standards are further described in the "Auditor's Responsibilities" section. We are independent of the parent company and the group in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled our ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinions.

Responsibilities of the Board of Directors and the Managing Director

The Board of Directors is responsible for the proposal for appropriations of the company's profit or loss. At the proposal of a dividend, this includes an assessment of whether the dividend is justifiable considering the requirements which the company's and the group's type of operations, size and risks place on the size of the parent company's and the group's equity, consolidation requirements, liquidity and position in general.

The Board of Directors is responsible for the company's organization and the administration of the company's affairs. This includes among other things continuous assessment of the company's and the group's financial situation and ensuring that the company's organization is designed so that the accounting, management of assets and the company's financial affairs otherwise are controlled in a reassuring manner. The Managing Director shall manage the ongoing administration according to the Board of Directors' guidelines and instructions and among other matters take measures that are necessary to fulfill the company's accounting in accordance with law and handle the management of assets in a reassuring manner.

Auditor's responsibility

Our objective concerning the audit of the administration, and thereby our opinion about discharge from liability, is to obtain audit evidence to assess with a reasonable degree of assurance whether any member of the Board of Directors or the Managing Director in any material respect:

- has undertaken any action or been guilty of any omission which can give rise to liability to the company, or
- in any other way has acted in contravention of the Companies Act, the Annual Accounts Act or the Articles of Association.

Our objective concerning the audit of the proposed appropriations of the company's profit or loss, and thereby our opinion about this, is to assess with reasonable degree of assurance whether the proposal is in accordance with the Companies Act.

Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with generally accepted auditing standards in Sweden will always detect actions or omissions that can give rise to liability to the company, or that the proposed appropriations of the company's profit or loss are not in accordance with the Companies Act. A further description of our responsibilities for the audit of the administration is available on the Swedish Inspectorate of Auditors' website: www.revisorsinspektionen.se/rn/showdocument/documents/rev_dok/revisors_ansvar.pdf. This description comprises part of the auditor's report.

Auditor's statement regarding the report on income tax information

The Board of Directors is responsible for the report on income tax information and for ensuring that it is prepared in accordance with Act (2023:340) on the disclosure of income tax information by certain large undertakings.

Our examination was conducted in accordance with FAR's recommendation RevR 21, "The auditor's statement regarding the report on income tax information." This means that our examination of the report on income tax information differs in focus and is substantially less extensive than an audit conducted in accordance with International Standards on Auditing (ISA) and generally accepted auditing standards in Sweden. We believe that this examination provides us with a sufficient basis for our opinion.

Our responsibility is to express an opinion on whether the company was obliged to publish a report on income tax information for the preceding financial year and, if so, whether the company has published such a report in accordance with Act (2023:340) on the disclosure of income tax information by certain large undertakings.

In our opinion, the company was under no obligation to publish a report on income tax information for the preceding financial year.

Stockholm, November 12, 2026
BDO Mälardalen AB

Johan Pharmanson
Authorized Public Accountant

Introduction +
Corporate governance +
Financial +
Other information
Shareholder information



4 OTHER INFORMATION

Introduction +
Corporate governance +
Financial +
Other information
→ Shareholder information

Shareholder information

FINANCIAL CALENDAR

Annual General Meeting	December 3, 2026
Quarterly Report (Sep-Nov)	January 26, 2027
Quarterly Report (Sep-Feb)	April 27, 2027
Quarterly Report (Sep-May)	June 29, 2027
Year-end report (Sep-Aug)	October 26, 2027

IR CONTACT

Anders Essen-Möller, CEO Diamyd Medical AB
Phone: +46 (0)705 51 06 79,
e-mail: anders.essen-moller@diamyd.com



Production: Diamyd Medical in partnership with Ventures Accelerated.
Photo: Mattias Bardå, Fredrik Larsson, Diamyd Medical's archive.

DIAMYD
MEDICAL

www.diamyd.com